CA2582908A1 - Macrocyclic sh2 domain binding inhibitors - Google Patents
Macrocyclic sh2 domain binding inhibitors Download PDFInfo
- Publication number
- CA2582908A1 CA2582908A1 CA002582908A CA2582908A CA2582908A1 CA 2582908 A1 CA2582908 A1 CA 2582908A1 CA 002582908 A CA002582908 A CA 002582908A CA 2582908 A CA2582908 A CA 2582908A CA 2582908 A1 CA2582908 A1 CA 2582908A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- alkoxy
- aryl
- compound
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003112 inhibitor Substances 0.000 title description 6
- -1 azido, amino Chemical group 0.000 claims abstract description 100
- 150000001875 compounds Chemical class 0.000 claims abstract description 88
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 32
- 102000014400 SH2 domains Human genes 0.000 claims abstract description 24
- 108050003452 SH2 domains Proteins 0.000 claims abstract description 24
- 239000001257 hydrogen Substances 0.000 claims abstract description 22
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 22
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 21
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 claims abstract description 20
- 150000001413 amino acids Chemical class 0.000 claims abstract description 19
- 230000003278 mimic effect Effects 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 9
- 239000012453 solvate Substances 0.000 claims abstract description 9
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 73
- 229930194542 Keto Natural products 0.000 claims description 38
- 125000003545 alkoxy group Chemical group 0.000 claims description 38
- 125000000468 ketone group Chemical group 0.000 claims description 38
- 125000001424 substituent group Chemical group 0.000 claims description 36
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 27
- 125000000623 heterocyclic group Chemical group 0.000 claims description 23
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 claims description 22
- 101150098203 grb2 gene Proteins 0.000 claims description 22
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 21
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 235000018102 proteins Nutrition 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims description 16
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 229940024606 amino acid Drugs 0.000 claims description 13
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims description 11
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 11
- 235000001014 amino acid Nutrition 0.000 claims description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 9
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims description 8
- 150000002148 esters Chemical group 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 7
- 102000007982 Phosphoproteins Human genes 0.000 claims description 6
- 108010089430 Phosphoproteins Proteins 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 5
- 125000005974 C6-C14 arylcarbonyl group Chemical group 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 5
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims description 4
- 229960001230 asparagine Drugs 0.000 claims description 4
- 235000009582 asparagine Nutrition 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000005089 alkenylaminocarbonyl group Chemical group 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 150000003573 thiols Chemical group 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- QFQYGJMNIDGZSG-YFKPBYRVSA-N (2r)-3-(acetamidomethylsulfanyl)-2-azaniumylpropanoate Chemical compound CC(=O)NCSC[C@H]([NH3+])C([O-])=O QFQYGJMNIDGZSG-YFKPBYRVSA-N 0.000 claims description 2
- BFNDLDRNJFLIKE-ROLXFIACSA-N (2s)-2,6-diamino-6-hydroxyhexanoic acid Chemical compound NC(O)CCC[C@H](N)C(O)=O BFNDLDRNJFLIKE-ROLXFIACSA-N 0.000 claims description 2
- XXGPNEDZNRZWPK-QMMMGPOBSA-N (2s)-2-(carboxyamino)-3-phenylpropanoic acid Chemical compound OC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XXGPNEDZNRZWPK-QMMMGPOBSA-N 0.000 claims description 2
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 claims description 2
- DWKNTLVYZNGBTJ-IBGZPJMESA-N (2s)-2-amino-6-(dibenzylamino)hexanoic acid Chemical compound C=1C=CC=CC=1CN(CCCC[C@H](N)C(O)=O)CC1=CC=CC=C1 DWKNTLVYZNGBTJ-IBGZPJMESA-N 0.000 claims description 2
- FNRJOGDXTIUYDE-ZDUSSCGKSA-N (2s)-2-amino-6-[benzyl(methyl)amino]hexanoic acid Chemical compound OC(=O)[C@@H](N)CCCCN(C)CC1=CC=CC=C1 FNRJOGDXTIUYDE-ZDUSSCGKSA-N 0.000 claims description 2
- WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 claims description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 claims description 2
- BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 claims description 2
- KNQHBAFIWGORKW-UHFFFAOYSA-N 2,3-diamino-3-oxopropanoic acid Chemical compound NC(=O)C(N)C(O)=O KNQHBAFIWGORKW-UHFFFAOYSA-N 0.000 claims description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 claims description 2
- GTVVZTAFGPQSPC-UHFFFAOYSA-N 4-nitrophenylalanine Chemical compound OC(=O)C(N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 2
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 2
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 claims description 2
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 claims description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 125000006323 alkenyl amino group Chemical group 0.000 claims description 2
- 125000004948 alkyl aryl alkyl group Chemical group 0.000 claims description 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 2
- JINBYESILADKFW-UHFFFAOYSA-N aminomalonic acid Chemical compound OC(=O)C(N)C(O)=O JINBYESILADKFW-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 2
- 125000001769 aryl amino group Chemical group 0.000 claims description 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- QNRXNRGSOJZINA-UHFFFAOYSA-N indoline-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)CC2=C1 QNRXNRGSOJZINA-UHFFFAOYSA-N 0.000 claims description 2
- 235000014705 isoleucine Nutrition 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 claims description 2
- PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 19
- WOXWUZCRWJWTRT-UHFFFAOYSA-N 1-amino-1-cyclohexanecarboxylic acid Chemical compound OC(=O)C1(N)CCCCC1 WOXWUZCRWJWTRT-UHFFFAOYSA-N 0.000 claims 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 1
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 claims 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 1
- 229960003104 ornithine Drugs 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract description 3
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 abstract description 2
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 44
- 239000000243 solution Substances 0.000 description 39
- 239000000203 mixture Substances 0.000 description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 34
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 32
- 125000005843 halogen group Chemical group 0.000 description 22
- 235000019439 ethyl acetate Nutrition 0.000 description 19
- 229910001868 water Inorganic materials 0.000 description 18
- 239000011347 resin Substances 0.000 description 16
- 229920005989 resin Polymers 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 101150041968 CDC13 gene Proteins 0.000 description 14
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 239000012267 brine Substances 0.000 description 12
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 239000007832 Na2SO4 Substances 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 150000001412 amines Chemical class 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- 229910052938 sodium sulfate Inorganic materials 0.000 description 11
- 235000011152 sodium sulphate Nutrition 0.000 description 11
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 150000002431 hydrogen Chemical group 0.000 description 10
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 101100180319 Mus musculus Itk gene Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000006798 ring closing metathesis reaction Methods 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 3
- 101150118364 Crkl gene Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 102000015617 Janus Kinases Human genes 0.000 description 3
- 108010024121 Janus Kinases Proteins 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 102000014384 Type C Phospholipases Human genes 0.000 description 3
- 108010079194 Type C Phospholipases Proteins 0.000 description 3
- 102000035181 adaptor proteins Human genes 0.000 description 3
- 108091005764 adaptor proteins Proteins 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000012146 running buffer Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 3
- QXTIBZLKQPJVII-UHFFFAOYSA-N triethylsilicon Chemical compound CC[Si](CC)CC QXTIBZLKQPJVII-UHFFFAOYSA-N 0.000 description 3
- XUHRVZXFBWDCFB-QRTDKPMLSA-N (3R)-4-[[(3S,6S,9S,12R,15S,18R,21R,24R,27R,28R)-12-(3-amino-3-oxopropyl)-6-[(2S)-butan-2-yl]-3-(2-carboxyethyl)-18-(hydroxymethyl)-28-methyl-9,15,21,24-tetrakis(2-methylpropyl)-2,5,8,11,14,17,20,23,26-nonaoxo-1-oxa-4,7,10,13,16,19,22,25-octazacyclooctacos-27-yl]amino]-3-[[(2R)-2-[[(3S)-3-hydroxydecanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoic acid Chemical compound CCCCCCC[C@H](O)CC(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H]1[C@@H](C)OC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CO)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC1=O)[C@@H](C)CC XUHRVZXFBWDCFB-QRTDKPMLSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 101100149252 Caenorhabditis elegans sem-5 gene Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 101150069913 Csk gene Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 101100484539 Drosophila melanogaster Vav gene Proteins 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 2
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 2
- 101000752722 Homo sapiens Apoptosis-stimulating of p53 protein 1 Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010032107 Non-Receptor Type 11 Protein Tyrosine Phosphatase Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 2
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 102000003901 Ras GTPase-activating proteins Human genes 0.000 description 2
- 108090000231 Ras GTPase-activating proteins Proteins 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 102100024547 Tensin-1 Human genes 0.000 description 2
- 108010088950 Tensins Proteins 0.000 description 2
- 101150042678 VAV1 gene Proteins 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000001815 biotherapy Methods 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 239000008180 pharmaceutical surfactant Substances 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Substances CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- YUGBZNJSGOBFOV-INIZCTEOSA-N (2s)-4-amino-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)N)C(O)=O)C3=CC=CC=C3C2=C1 YUGBZNJSGOBFOV-INIZCTEOSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- VGDSDERYSQCJRS-UHFFFAOYSA-N 1,2-dichloroethane;trimethoxymethane Chemical compound ClCCCl.COC(OC)OC VGDSDERYSQCJRS-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VCIVAWBKUQJNSX-UHFFFAOYSA-N 1-(9h-fluoren-9-ylmethoxycarbonylamino)cyclohexane-1-carboxylic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)NC1(C(=O)O)CCCCC1 VCIVAWBKUQJNSX-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- QPKYUTPXCLMLSN-UHFFFAOYSA-N 1-chlorocyclohexane-1-carbonitrile Chemical compound N#CC1(Cl)CCCCC1 QPKYUTPXCLMLSN-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- FTLUYABUJZUQON-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonyl-prop-2-enylamino]acetic acid Chemical class CC(C)(C)OC(=O)N(CC=C)CC(O)=O FTLUYABUJZUQON-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- VQNDBXJTIJKJPV-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridine Chemical compound C1=CC=NC2=NNN=C21 VQNDBXJTIJKJPV-UHFFFAOYSA-N 0.000 description 1
- ATAFDSCDEDHMOK-UHFFFAOYSA-N 3,3-diaminopropanoic acid Chemical compound NC(N)CC(O)=O ATAFDSCDEDHMOK-UHFFFAOYSA-N 0.000 description 1
- VHVGNTVUSQUXPS-JAMMHHFISA-N 3-Phenylserine Chemical compound OC(=O)[C@@H](N)C(O)C1=CC=CC=C1 VHVGNTVUSQUXPS-JAMMHHFISA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
- 101710125089 Bindin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- QUMCIHKVKQYNPA-RUZDIDTESA-N C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC Chemical compound C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC QUMCIHKVKQYNPA-RUZDIDTESA-N 0.000 description 1
- 125000005914 C6-C14 aryloxy group Chemical group 0.000 description 1
- 101100447914 Caenorhabditis elegans gab-1 gene Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101100503636 Danio rerio fyna gene Proteins 0.000 description 1
- 101100314281 Danio rerio trappc11 gene Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 101000652725 Drosophila melanogaster Transcription initiation factor TFIID subunit 5 Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 101150036586 FES gene Proteins 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 101150018272 FYN gene Proteins 0.000 description 1
- 101150040897 Fgr gene Proteins 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102100037759 GRB2-associated-binding protein 2 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 108091008603 HGF receptors Proteins 0.000 description 1
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 1
- 101001024902 Homo sapiens GRB2-associated-binding protein 2 Proteins 0.000 description 1
- 101001120056 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit alpha Proteins 0.000 description 1
- 101001120097 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit beta Proteins 0.000 description 1
- 101001116549 Homo sapiens Protein CBFA2T2 Proteins 0.000 description 1
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 description 1
- 101000927796 Homo sapiens Rho guanine nucleotide exchange factor 7 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- JZKXXXDKRQWDET-QMMMGPOBSA-N L-m-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(O)=C1 JZKXXXDKRQWDET-QMMMGPOBSA-N 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- FYYSQDHBALBGHX-YFKPBYRVSA-N N(alpha)-t-butoxycarbonyl-L-asparagine Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC(N)=O FYYSQDHBALBGHX-YFKPBYRVSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101100381429 Oryza sativa subsp. japonica BADH2 gene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 102100028516 Receptor-type tyrosine-protein phosphatase U Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000038012 SFKs Human genes 0.000 description 1
- 108091008118 SFKs Proteins 0.000 description 1
- 102000000395 SH3 domains Human genes 0.000 description 1
- 108050008861 SH3 domains Proteins 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000000887 Transcription factor STAT Human genes 0.000 description 1
- 108050007918 Transcription factor STAT Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- WNNNWFKQCKFSDK-UHFFFAOYSA-N allylglycine Chemical group OC(=O)C(N)CC=C WNNNWFKQCKFSDK-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- NVYVHAPFRUEAJN-UHFFFAOYSA-N anisole;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC=C1 NVYVHAPFRUEAJN-UHFFFAOYSA-N 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 108700000711 bcl-X Proteins 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- UNOMOKBVBBHHMU-UHFFFAOYSA-N benzylidene-dicyclohexyl-(4,4-dichlorocyclohexyl)-lambda5-phosphane ruthenium Chemical compound [Ru].ClC1(Cl)CCC(CC1)P(=Cc1ccccc1)(C1CCCCC1)C1CCCCC1 UNOMOKBVBBHHMU-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125876 compound 15a Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002621 immunoprecipitating effect Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 229910052740 iodine Chemical group 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 238000005710 macrocyclization reaction Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000001869 matrix assisted laser desorption--ionisation mass spectrum Methods 0.000 description 1
- JZKXXXDKRQWDET-UHFFFAOYSA-N meta-tyrosine Natural products OC(=O)C(N)CC1=CC=CC(O)=C1 JZKXXXDKRQWDET-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- AKEYUWUEAXIBTF-UHFFFAOYSA-N n-methylnaphthalen-1-amine Chemical compound C1=CC=C2C(NC)=CC=CC2=C1 AKEYUWUEAXIBTF-UHFFFAOYSA-N 0.000 description 1
- NVSYANRBXPURRQ-UHFFFAOYSA-N naphthalen-1-ylmethanamine Chemical compound C1=CC=C2C(CN)=CC=CC2=C1 NVSYANRBXPURRQ-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- CCTIOCVIZPCTGO-BYPYZUCNSA-N phosphoarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)NP(O)(O)=O CCTIOCVIZPCTGO-BYPYZUCNSA-N 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 238000000252 photodiode array detection Methods 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001469 poly(aryloxy)thionylphosphazene Polymers 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 230000017363 positive regulation of growth Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000003836 solid-state method Methods 0.000 description 1
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 108091005990 tyrosine-phosphorylated proteins Proteins 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/5532—Seven-(or more) membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Disclosed are compounds for inhibiting the binding of an SH2 domain-containing protein, for example, a compound of formula (I): FORMULA (I) wherein R1 is a lipophile; R2, in combination with the phenyl ring, is a phenylphosphate mimic group or a protected phenylphosphate mimic group; R3 is, for example, hydrogen, azido, amino, oxalylamino, carboxy alkyl, alkoxycarbonyl alkyl, aminocarbonyl alkyl, or alkyl carbonylamino; R6 is a linker; AA is an amino acid; and n is 1 to 6; or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof. Also disclosed are pharmaceutical compositions and methods of use of such compounds.
Description
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of U.S. Provisional Patent Application No.
60/614,800, filed September 30, 2004, the disclosure of which is incorporated by reference.
FIELD OF THE INVENTION
[0001] This application claims the benefit of U.S. Provisional Patent Application No.
60/614,800, filed September 30, 2004, the disclosure of which is incorporated by reference.
FIELD OF THE INVENTION
[0002] This invention relates to macrocyclic peptides, compositions comprising these peptides,- and methods of using these peptides, e.g., in inhibiting SH2 domain-containing protein from binding with a phosphoprotein and in the prevention or treatment of a disease such as cancer in a mammal.
BACKGROUND OF THE INVENTION
BACKGROUND OF THE INVENTION
[0003] The pharmaceutical industry is in search for new classes of compounds for the therapy and prophylaxis of proliferative diseases such as cancer, autoirnmune diseases, and hyperproliferative skin disorders such as psoriasis. These diseases or disorders affect a large portion of the population, leading to suffering and possibly death.
[0004] Some of these diseases or disorders may involve signal transduction.
Signal transduction is critical to normal cellular homeostasis and is the process of relaying extracellular messages, e.g., chemical messages in the form of growth factors, hormones and neurotransmitters, via receptors, e.g., cell-surface receptors, to the interior of the cell.
Protein-tyrosine kinases play a central role in this biological function.
Among others, these enzymes catalyze the phosphorylation of specific tyrosine residues to form tyrosine phosphorylated residues. Examples of this class of enzymes include the PDGF
receptor, the FGF receptor, the HGF receptor, members of the EGF receptor family such as the EGF
receptor, erb-B2, erb-B3 and erb-B4, the src kinase family, Fak kinase and the Jak kinase family. The tyrosine-phosphorylated proteins are iinvolved in a range of inetabolic processes, from proliferation and growth to differentiation.
Signal transduction is critical to normal cellular homeostasis and is the process of relaying extracellular messages, e.g., chemical messages in the form of growth factors, hormones and neurotransmitters, via receptors, e.g., cell-surface receptors, to the interior of the cell.
Protein-tyrosine kinases play a central role in this biological function.
Among others, these enzymes catalyze the phosphorylation of specific tyrosine residues to form tyrosine phosphorylated residues. Examples of this class of enzymes include the PDGF
receptor, the FGF receptor, the HGF receptor, members of the EGF receptor family such as the EGF
receptor, erb-B2, erb-B3 and erb-B4, the src kinase family, Fak kinase and the Jak kinase family. The tyrosine-phosphorylated proteins are iinvolved in a range of inetabolic processes, from proliferation and growth to differentiation.
[0005] Protein-tyrosine phosphorylation is known to be involved in modulating the activity of some target enzymes as well as in generating specific complex networks involved in signal transduction via various proteins containing a specific amino acid sequence called an Src homology region or SH2 domain (see, e.g., Proc. Natl.
Acad. Sci.
USA, 90, 5891 (1-990)). A malfunction in this protein-tyrosine phosphorylation through tyrosine kinase overexpression or deregulation is manifested by various oncogenic and (hyper-) proliferative disorders such as cancer, inflammation, autoimmune disease, hyper-proliferative skin disorders, such as psoriasis, and allergy/asthma. SH2-and/or SH3-comprising proteins that play a role in cellular signaling and transformation include, but are not limited to, the following: Src, Lck, Eps, ras GTPase-activating protein (GAP), phospholipase C, phosphoinositol-3 '(PI-3) kinase, Fyn, Lyk, Fgr, Fes, ZAP=70, Sem-5, p85, SHPTPI, SHPTP2, corkscrew, Syk, Lyn, Yes, Hck, Dsrc, Tec, Atk/Bpk, Itk/Tsk, Arg, Csk, tensin, Vav, Emt, Grb2, BCR-Abl, Shc, Nck, Crk, CrkL, Syp, Blk, 113TF, 91TF, Tyk2, especially Src, phospholipase c, phoshoinositol-3 (PI-3) kinase, Grb2, BCR-Abl, Shc, Nck, Crk, CrkL, Syp, Blk, 113TF, 91 TF, and Tyk2. A direct link has been established between activated receptor kinases and Ras with the finding that the mammalian Grb2 protein, a 26 kilo Dalton (kD) protein comprising,a single SH2 and two SH3 domains bind to proline-rich sequences present in the Sos exchange factor.
Acad. Sci.
USA, 90, 5891 (1-990)). A malfunction in this protein-tyrosine phosphorylation through tyrosine kinase overexpression or deregulation is manifested by various oncogenic and (hyper-) proliferative disorders such as cancer, inflammation, autoimmune disease, hyper-proliferative skin disorders, such as psoriasis, and allergy/asthma. SH2-and/or SH3-comprising proteins that play a role in cellular signaling and transformation include, but are not limited to, the following: Src, Lck, Eps, ras GTPase-activating protein (GAP), phospholipase C, phosphoinositol-3 '(PI-3) kinase, Fyn, Lyk, Fgr, Fes, ZAP=70, Sem-5, p85, SHPTPI, SHPTP2, corkscrew, Syk, Lyn, Yes, Hck, Dsrc, Tec, Atk/Bpk, Itk/Tsk, Arg, Csk, tensin, Vav, Emt, Grb2, BCR-Abl, Shc, Nck, Crk, CrkL, Syp, Blk, 113TF, 91TF, Tyk2, especially Src, phospholipase c, phoshoinositol-3 (PI-3) kinase, Grb2, BCR-Abl, Shc, Nck, Crk, CrkL, Syp, Blk, 113TF, 91 TF, and Tyk2. A direct link has been established between activated receptor kinases and Ras with the finding that the mammalian Grb2 protein, a 26 kilo Dalton (kD) protein comprising,a single SH2 and two SH3 domains bind to proline-rich sequences present in the Sos exchange factor.
[0006] ' The significance of ras-regulatory proteins in human tumors is also highlighted by the critical role of Grb2 in BCR=Ab1 mediated oncogenesis (J. Exp. Med., 179, 167-175 (1994)). Involved in the binding of SH2 domains with phosphotyrosine ("pTyr") containing ligands is the interaction of the doubly ionized pTyr phosphate with two invariant arginine residues in a well-formed pocket. These arginine-phosphate interactions are particularly significant to the overall binding, such that high affinity binding is usually lost by removal of the phosphate group.
[0007] There exists a need for molecules that have an ability to mimic the structure of the phosphotyrosine peptide binding site, as well as a need for compounds that have the ability to disrupt the interaction between SH2 domains of proteins (e.g., regulatory proteins) for example that of Grb2, and proteins with phosphorylated moieties. There further exists a need for compounds suitable for use=in the therapy or prophylaxis of proliferative diseases or conditions, as well as in diagnosis, assays, and testing.
[0008] These and other advantages of the present invention will be apparent from the description as set forth below.
BRIEF SUMMARY OF THE INVENTION
BRIEF SUMMARY OF THE INVENTION
[0009] The invention provides, in aspect, compounds of formula (I):
R1Y \
R6 (AA)n Rz (I) [0010] whereinRl is a lipophile; R2, in combination with the phenyl ring, is a phenylphosphate mimic group or a protected phenylphosphate mimic group; R3 is hydrogen (unsubstituted), azido, amino, oxalylamino, carboxy alkyl, alkoxycarbonyl alkyl, aminocarbonyl alkyl, or alkyl carbonylamino; wherein the alkyl portion of any of the R3 groups may be optionally substituted with a suitable substituent, for example, one or more selected from the group consisting of halo, hydroxy, carboxyl, amino, amino alkyl, alkyl, alkoxy, and keto, and any combination thereof; R6 is a linker; AA is an amino acid or fragment thereof; and n is 1 to 6; or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof; pharmaceutical compositions thereof, and methods of use thereof.
R1Y \
R6 (AA)n Rz (I) [0010] whereinRl is a lipophile; R2, in combination with the phenyl ring, is a phenylphosphate mimic group or a protected phenylphosphate mimic group; R3 is hydrogen (unsubstituted), azido, amino, oxalylamino, carboxy alkyl, alkoxycarbonyl alkyl, aminocarbonyl alkyl, or alkyl carbonylamino; wherein the alkyl portion of any of the R3 groups may be optionally substituted with a suitable substituent, for example, one or more selected from the group consisting of halo, hydroxy, carboxyl, amino, amino alkyl, alkyl, alkoxy, and keto, and any combination thereof; R6 is a linker; AA is an amino acid or fragment thereof; and n is 1 to 6; or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof; pharmaceutical compositions thereof, and methods of use thereof.
[0011] In another aspect, the invention provides compounds of the formula II:
R' 1 CH2)m-N ~ NHZ
HN
, I \ NH o R3 o R
(II)~
wherein Rl and Rl' are the same and are CI -C6 alkyl or Rl and Rl' together form a C4-C8 cycloalkyl; R2, in combination with the phenyl ring, is a phenylphosphate mimic group or a protected phenylphosphate mimic group; R3 is hydrogen, azido, amino, oxalylamino, carboxy CI-C6 alkyl, C1-C6 alkoxycarbonyl C1-C6 alkyl, aminocarbonyl C1-C6 alkyl, or C1-C6 alkyl carbonylamino; wherein the alkyl portion of R3 may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof;
R4 and R5, independently, are hydrogen, C1-C6 alkyl, C4-C8 cycloalkyl, or heterocyclyl=, or R4 and R5 together form a C4-C8 cycloalkyl or heterocyclyl;
R6 is a group having 1-6 carbon atoms, .which may be optionally have a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof; and m is 1 or 2;
R' 1 CH2)m-N ~ NHZ
HN
, I \ NH o R3 o R
(II)~
wherein Rl and Rl' are the same and are CI -C6 alkyl or Rl and Rl' together form a C4-C8 cycloalkyl; R2, in combination with the phenyl ring, is a phenylphosphate mimic group or a protected phenylphosphate mimic group; R3 is hydrogen, azido, amino, oxalylamino, carboxy CI-C6 alkyl, C1-C6 alkoxycarbonyl C1-C6 alkyl, aminocarbonyl C1-C6 alkyl, or C1-C6 alkyl carbonylamino; wherein the alkyl portion of R3 may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof;
R4 and R5, independently, are hydrogen, C1-C6 alkyl, C4-C8 cycloalkyl, or heterocyclyl=, or R4 and R5 together form a C4-C8 cycloalkyl or heterocyclyl;
R6 is a group having 1-6 carbon atoms, .which may be optionally have a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof; and m is 1 or 2;
[0012] or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof;
pharmaceutical compositions thereof, and methods of use thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
pharmaceutical compositions thereof, and methods of use thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 depicts a method for preparing compounds 3 and 4. Reagents:
(i) HOBt, DIPCDI, DMF; (ii) a) TFA; b) aqueous NaHCO3; c) HOBt, DIPCDI, DMF; (iii) 20% piperidine in DMF; (iv) N-Fmoc-Ac6c-OH, HOBt, DIPCDI, DMF for 7a; Et2N/DMF
then Boc-Ac6c-OH, HOAT, EDCI, DMF for 6b; (v) 20% piperidine in DMF; (vi) HOAt, EDCI=HC1, DMF for 8a; TFA-anisole (10:1) for 8b; (vii) [((PCy3)(Im(Mes)2)Ru=CHPh)], CH2C12i (viii) TFA, H20.
(i) HOBt, DIPCDI, DMF; (ii) a) TFA; b) aqueous NaHCO3; c) HOBt, DIPCDI, DMF; (iii) 20% piperidine in DMF; (iv) N-Fmoc-Ac6c-OH, HOBt, DIPCDI, DMF for 7a; Et2N/DMF
then Boc-Ac6c-OH, HOAT, EDCI, DMF for 6b; (v) 20% piperidine in DMF; (vi) HOAt, EDCI=HC1, DMF for 8a; TFA-anisole (10:1) for 8b; (vii) [((PCy3)(Im(Mes)2)Ru=CHPh)], CH2C12i (viii) TFA, H20.
[0014] Figure 2 depicts the formulas of compounds 3 and 4 in accordance with an embodiment of the invention and of open-chain compound 2.
[0015] Figure 3 depicts a solid-state method for preparing compound 9b, open-chain compound 2, and 15a-15c, 17a-17b, and 18a-18b.
[0016] Figure 4 depicts a reaction scheme to prepare compound 24 in accordance with an embodiment of the invention.
DETAILED DESCRIPTION OF THE INVENTION
DETAILED DESCRIPTION OF THE INVENTION
[0017] An aspect of the present invention is predicated on the coricept that binding affinity for SH2 domain proteins can be envisioned to increase by a conformational constraint in a ligand. The conformational constraint is believed to lead to certain advantages, e.g., a reduction in binding entropy penalty. Binding of natural pTyr-containing ligands to Grb2 SH2 domains takes place in a(3-bend fashion, with key interactions occurring in a pTyr binding pocket as well as in a proximal pocket which ligates the amino acid side chain of a pY+2 Asn residue. The present invention provides a novel platform which is expected provide enhanced'binding outside the pTyr pocket.
[0018] , Accordingly, the present invention provides, in an embodiment, compounds of formula (I):
R1Y \
(AA~, ~ ~
O
~/ R3 (I) wherein Rl can be a lipophile; R2, in combination with the phenyl ring, can be a phenylphqsphate. mimic group or a protected phenylphosphate mimic' group; R3 can be, for example, hydrogen, azido, amino, xalylamino, carboxy C1-C6 alkyl, C,I-C6 alkoxycarbonyl C1-C6 alkyl, aminocarbonyl C1-C6 alkyl, or C1-C6 alkyl carbonylamino; wherein the alkyl portion of any of the R3 groups may be optionally substituted, e.g., with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C1-C6 alkyl, CI -C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof; R6 is a linker; AA is an amino acid or fragment thereof, and the amino acid can be natural or synthetic; and n can be any suitable integer, e.g., 1 to 6; or.a pharmaceutically acceptable salt, sterebisomer, solvate, or hydrate thereof. In an embodiment, n is 2 to 5, preferably 2 or 3, and more preferably 2.
R1Y \
(AA~, ~ ~
O
~/ R3 (I) wherein Rl can be a lipophile; R2, in combination with the phenyl ring, can be a phenylphqsphate. mimic group or a protected phenylphosphate mimic' group; R3 can be, for example, hydrogen, azido, amino, xalylamino, carboxy C1-C6 alkyl, C,I-C6 alkoxycarbonyl C1-C6 alkyl, aminocarbonyl C1-C6 alkyl, or C1-C6 alkyl carbonylamino; wherein the alkyl portion of any of the R3 groups may be optionally substituted, e.g., with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C1-C6 alkyl, CI -C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof; R6 is a linker; AA is an amino acid or fragment thereof, and the amino acid can be natural or synthetic; and n can be any suitable integer, e.g., 1 to 6; or.a pharmaceutically acceptable salt, sterebisomer, solvate, or hydrate thereof. In an embodiment, n is 2 to 5, preferably 2 or 3, and more preferably 2.
[0019] The linker R6 connects the 0-carbon (shown as 1 in formula I) of tlie pTyr mimetic to the carbon (shown as 2 in formula I) adjacent to the amino group (NH) of the first amino acid. The bond connecting the linker to the linking sites can have any suitable configuration (R, S, or RIS).
[0020] Rl can be any suitable lipophile, e.g., a hydrophobic or nonpolar group, such as an alkyl, alkoxy, alkenyl, alkynyl, aryl, aryloxy, aryl alkoxy, alkylaryl, alkyloxy aryl, arylalkyl, alkylamino, arylalkylamino, alkenylamino, arylamino, aryloxy alkyl, heterocyclyl, heterocyclyloxy, aryl.heterocyclyl alkyl, heterocyclyl alkyl, heterocyclyl alkoxy, aryl heterocyclyl, aryl heterocyclyloxy, alkyl arylalkyl, alkoxy arylalkyl, and alkoxy arylalkoxy, and any combination thereof, optionally substituted or in combination with one or more groups such as alkyl, keto; ester, amino, aminocarbonyl, ureido, hydroxyl, thiol, cyano, alkoxy, and halo. Electron rich groups such as aromatic ring systems such as naphthyl, biphenyl, anthracenyl, and fluorenyl, can be part of examples of Ri in accordance with an embodiment of the invention. In the various Rl groups listed above, the alkyl portion can have 1-6 carbon atoms, the aryl portion can have 6-14 carbon atoms, alkenyl and alkynyl portions can have 2-6 carbon atoms, and the heterocyclyl portion can have 3-7 ring atoms including at least one of N, S, and O.
[0021] A phenylphosphate mimic group can be one that has the functional property of the phosphorylated end of tyrosine-phosphorylated sequences; e.g., it can replicate the interaction of phenylphosphate with proteins. The interaction may involve any number of mechanisms, including geometry, size, and/or charge. A protected phenylphosphate mimetic is a phenylphosphate mimic that contains a protecting group that releases the mimetic, e.g., in a biological environment, such as due to chemical or' enzymatic hydrolysis.
In embodiments, the protecting groups can be esters or amides.
In embodiments, the protecting groups can be esters or amides.
[0022] ' The present invention also provides pharmaceutically acceptable salts of the above compounds including alkali or amine salts. The acidic groups, e.g., carboxylic, phosphoric, or phosphonic groups, of the compound may be converted to salts known to those skilled in the art, for example, a salt of an alkali metal (e.g., sodium or potassium), alkaline earth metal (e.g., calcium), or ammonium salt.
[0023] ' In the above embodiments of the invention, amino acid (AA) may be selected from the group consisting of glycine, alanine, valine, norvaline, leucine, iso-leucine, norleucine, a-amino n-decanoic acid, serine, homoserine, threonine, methionine, cysteine, S-acetylaminomethyl-cysteine, proline, trans-3- and trans-4-hydroxyproline, phenylalanine, tyrosine, 4-aminophenylalanine, 4- nitrophenylalanine, 4-chlorophenylalanine, carboxyphenylalanine, (3-phenylserine, [3-hydroxyphenylalanine, phenylglycine, a-naphthyl4lanine, cyclohexylalanine, cyclohexylglycine, tryptophan, indoline-2-carboxylic acid, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, aspartic acid, asparagine, aminomalonic acid, aminomalonic acid monoamide, glutamic acid, glutamine, histidine, arginine, lysine, N'-benzyl-N'-methyl-lysine, N',N'-dibenzyl-lysine, 6-hydroxylysine, omithine, a-aminocyclopentane carboxylic acid, a-aminocyclohexane carboxylic acid, a-aminocycloheptane carboxylic acid,.a-(2-amino-2-norbornane)-carboxylic acid, a,y-diaminobutyric acid and a,(3-diaminopropionic acid, homophenylalanine, and a-tert-butylglycine, and any combination thereof, specifically asparagine and a-aminocyclohexane carboxylic acid.
[0024] In accordance with an embodiment, the invention provides compounds of formula (Ia) Rl NH NH2 , ~ O
0'.6 ~
O
R2 R4 (Ia), wherein R4 and R5, independently, are hydrogen, C1-C6 alkyl, C4-C8 cycloalkyl, or heterocyclyl, or R4 and R5 together form a C4-C8 cycloalkyl or a heterocyclyl;
Rl-R3 and R6 being as described above.
0'.6 ~
O
R2 R4 (Ia), wherein R4 and R5, independently, are hydrogen, C1-C6 alkyl, C4-C8 cycloalkyl, or heterocyclyl, or R4 and R5 together form a C4-C8 cycloalkyl or a heterocyclyl;
Rl-R3 and R6 being as described above.
[0025] In the embodiments above, examples of Rl can include C1-C6 alkyl carbonyl, C6-C14 aryl carbonyl, C6-C14 aryl C1-C6 alkyl carbonyl, C6-C14 aryl C1-C6 alkylamino carbonyl, C6-C14 aryl C1-C6 alkyl, C6-C14 aryl heterocyclyl C1-C6 alkyl, C6-C14 aryl heterocyclyl C1-C6 alkyl carbonyl, C1-C6 alkylaminocarbonyl, C2-C6 alkenyl aminocarbonyl, C6-arylaminocarbonyl, C1-C6 alkoxy C1-C6 alkyl, C1-C6 alkoxy C1-C6 alkyl carbonyl, C6-C14 aryloxy C1-C6 alkyl, C6-C14 aryloxy Cl =C6 alkyl carbonyl, C6-C14 aryl C1-C6 alkoxy C1-C6 alkyl, and C6-C14 aryl CI-C6 alkoxy C1-C6 alkyl carbonyl, wherein the aryl portion may be optionally substituted or in combination with one or more groups such as alkyl, keto, ester, amino, aminocarbonyl, ureido, hydroxyl, thiol, cyano, alkoxy, and halo.
[0026] In the embodiments above, examples of R2 can include hydroxyl, carboxyl, formyl, carboxy C1-C6 alkyl, carboxy C1-C6 alkoxy, dicarboxy CI-C6 alkyl, dicarboxy C1-C6 alkyloxy, dicarboxyhalo CI-C6 alkyl, dicarboxyhalo CI-C6 alkyloxy, phosphono, phosphono C1-C6 alkyl, phosphonohalo CI-C6 alkyl, phosphoryl, phosphoryl C1-C6 alkyl, and phosphoryl CI-C6 alkoxy, carboxy C1-C6 alkylamino, oxalylamino, RSO2NH-wherein R
can be CI -C6 alkyl, halo CI -C6 alkyl, C6-C14 aryl, C6-C14 aryl C1-C6 alkyl, or trifluoro Ci-C6 alkyl, C6-C14 aryl CI-C6 alkyl, phosphino C1-C6 alkyl, C1-C6 alkyl phosphirio C1-C6 alkyl, C6-C14 aryl, and C6-C14 aryl C1-C6 alkyl, wherein the alkyl portion of the substituents may be optionally substituted, e.g., with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, CI-C6 alkyl, CI-C6 alkoxy, and keto, and any combination thereof.
can be CI -C6 alkyl, halo CI -C6 alkyl, C6-C14 aryl, C6-C14 aryl C1-C6 alkyl, or trifluoro Ci-C6 alkyl, C6-C14 aryl CI-C6 alkyl, phosphino C1-C6 alkyl, C1-C6 alkyl phosphirio C1-C6 alkyl, C6-C14 aryl, and C6-C14 aryl C1-C6 alkyl, wherein the alkyl portion of the substituents may be optionally substituted, e.g., with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, CI-C6 alkyl, CI-C6 alkoxy, and keto, and any combination thereof.
[0027] R3 in any of the embodiments, can be, for example, hydrogen, azido, amino, oxalylamino, carboxy C1-C6 alkyl, C1-C6 alkoxycarbonyl C1-C6 alkyl, aminocarbonyl C1-C6 alkyl, or C1-C6 alkyl carbonylamino; wherein the alkyl portion of any of the R3 groups may be optionally substituted, e.g., with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, amino Cl-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof.
[0028] R4 and R5, independently, are hydrogen, CI-C6 alkyl, C4-C8 cycloalkyl, or heterocyclyl, or R4 and R5 together form a C4-C8 cycloalkyl, e.g., cyclohexyl, or a heterocyclyl.
[0029] - R6 in any of the embodiments can be a substituted or unsubstituted group having 1-6 carbon atoms, for example, a hydrocarbyl group, such as an unsaturated hydrocarbyl group, optionally further having a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, CI-C6 alkyl, CI-C6 alkoxy, and keto, and any combination thereof.
[0030] In specific embodiments; the invention provides compounds of f=ormulas (lb)-(Id):
R6 = O
HN
I ~ NH O
R2 R4 (lb), O
R1~~NH NH2 R6 = O
HN
NH O
(Ic), and R6 = O
HN
NH O
(Id), wherein Rl-R6 can be as described 'above.
R6 = O
HN
I ~ NH O
R2 R4 (lb), O
R1~~NH NH2 R6 = O
HN
NH O
(Ic), and R6 = O
HN
NH O
(Id), wherein Rl-R6 can be as described 'above.
[0031] .' In the embodiments of the invention, specifically, Rl can be C1-C6 alkyl carbonyl, C6-C14 aryl carbonyl, C6-C14 aryl Cl-C6 alkyl carbonyl, C6-C14 aryl Cl-C6 alkylamino carbonyl, C6-C14 aryl heterocyclyl C1-C6 alkyl carbonyl, C1-C6 alkylaminocarbonyl, C2-C6 alkenylaminocarbonyl, C6-C14 arylamino carbonyl, Cl-alkoxy CI-C6 alkyl carbonyl, C6-C14 aryloxy C1-C6 alkyl carbonyl, or,C6-C14 aryl Ci-C6 alkoxy C1-C6 alkyl carbonyl, whereiin the aryl portion may be unsubstituted'or substituted, e.g., with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C1-C6 alkyl, CI-C6 alkyl, 'Cl-C6 alkoxy, and keto, and any combination thereof. [0032] In the embodiments of the invention, R2 can be hydroxyl, carboxyl, formyl, carboxy C1-C6 alkyl, carboxy C1-C6 alkoxy, dicarboxy C1-C6 alkyl, dicarboxy C1-alkyloxy, -dicarboxyhalo C1-C6 alkyl, dicarboxyhalo Cl-C6 alkyloxy,.phosphono, phosphono C1-C6 alkyl, phosphonohalo C1-C6 alkyl, phosphoryl, phosphoryl C1-CG alkyl,-or phosphoryl C1-C6 alkoxy, wherein the alkyl or alkoxy portion may be optionally substituted with a substituent, e.g., selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof.
[0033] In the embodiments of the invention, R3 can be hydrogen (unsubstituted), azido, amino, oxalylamino, carboxy C1-C6 alkyl, C1-C6 alkoxycarbonyl C1-C6 alkyl,.
aminocarbonyl C1-C6 alkyl, and C1=C6 alkylcarbonylamino; wherein the alkyl portion of R3 may be optionally substituted with a substituent, e.g., selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C1-C6 alkyl, CI-C6 alkyl, Cl-C6 alkoxy, and keto, and any combination thereof.
[0034] In the embodiments of the invention, R4 and R5, independently, can be hydrogen, C1-C6 alkyl, cycloalkyl, heterocyclyl, or together form cycloalkyl or beterocyclyl, wherein the cycloalkyl can be a C3-C7 cycloalkyl, and the heterocyclyl can be a 3-7 membered ring with at least one of N, 0, and S.
[0035] In the embodiments of the invention, R6 can be a C2-C6 alkenylenyl or alkynylenyl group, specifically alkenylenyl, any of which may be optionally siubstituted, e.g., with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof.
[0036] In a specific embodiment, Rl-Rb are together as described in paragraphs [0027]-[0031].
[0037] In the embodiments of the invention, RI can be C6-C14 aryl C1-C6 alkylamino carbonyl, for example, Clo aryl C1-C6 alkylamino carbonyl, such as naphthyl methylamino carbonyl, e.g., 1-naphthyl methylamino.
[0038] In the embodiments of the invention, a specific example of R2 can be phosphono C1-C6 alkyl, optionally substituted with a substituerit, e.g., selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, alkyl, alkoxy, and keto, and any combination thereof; particularly, R2 can be phosphonomethyl.
[0039] In the embodiments of the invention, R3 can be carboxy C1-C6 alkyl, e.g., carboxymethyl.
[0040] In the embodiments of the invention, R6 can be allyl.
[0041:] The present invention also provides corapounds of the formula II:
R'1 CHz)m-N NHz R~
R6=
NH p s (II), wherein Rl and Rl' are the same and are C1-C6 alkyl or Rl and Rl' together form a C4-C$
cycloalkyl; R2, in combination with the phenyl ring, is a phenylphosphate mimic group or a protected phenylphosphate mimic group; R3 is hydrogen, azido, amino, oxalylamino, carboxy C1-C6 alkyl, C1-C6 alkoxycarbonyl C1-C6 alkyl, aminocarbonyl CI-C6 alkyl, or C1-C6 alkyl carbonylamino; wherein the alkyl portion of R3 may be optionally substituted with a substrtuent selected from the group consisting of halo, hydroxy, c.arboxyl,arnino, amino C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination tliereof; R4 and R5, independently, are hydrogen, C1-C6 alkyl, C4-C8 cycloalkyl, or heterocyclyl, or R4 and R5 together form a C4-C8 cycloalkyl or heterocyclyl;
R6 is a group having 1-6 carbon atoms, which may be optionally have a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C1-C6 alkyl, C1-C6 alkoxy., and keto, and any combination thereof; and m is 1 or 2;
or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof; and specifically, compounds wherein m is 1.
[0042] In an embodiment of the compounds of formula II, Rl and Rl' together form a C4-C8 cycloalkyl, e.g., cyclohexyl.
[0043] In any of the embodiments of the compounds of formula 11, R2 is hydroxyl, carboxyl, formyl, carboxy C1-C6 alkyl, carboxy C1-C6 alkoxy, dicarbqxy C1-C6 alkyl, dicarboxy C1-C6 alkyloxy, dicarboxyhalo C1-C6 alkyl, dicarboxyhalo C1-C6-alkyloxy, phosphono, phosphono C1-C6 alkyl, phosphonohalo C1-C6 alkyl, phosphoryl, phosphoryl Ct-C6 alkyl, and phosphoryl Cl-C6 alkoxy, carboxy C1-C6 alkylamino, oxalylamino, RSO2NH- wherein R can be C1-C6 alkyl, halo C1-C6 alkyl,'C6-C14 aryl, C6-C14 aryl CI-C6 alkyl, or trifluoro C1-C6 alkyl, C6-C14 aryl C1-C6 alkyl, phosphino CI-C6 alkyl, CI-C6 alkyl phosphino C1-C6 alkyl, C6-C14 aryl, and C6-C14 aryl C1-C6 alkyl, wherein the alkyl and alkoxy portions of R2 may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto; and any combination thereof; specifically, R2 is hydroxyl, carboxyl, formyl, carboxy C1-C6 alkyl, carboxy C1-C6 alkoxy, dicarboxy C1-C6 alkyl, dicarboxy C1-alkyloxy, dicarboxyhalo C1-C6 alkyl, dicarboxyhalo C1-C6 alkyloxy, phosphono, phosphono C1-C6 alkyl, phosphonohalo CI-C6 alkyl, phosphoryl, phosphoryl C1-C6 alkyl, or phosphoryl CI -C6 alkoxy, wherein the alkyl and alkoxy portions may be optionally substituted with a substituent selected from the group. consisting of halo, hydroxy, carboxyl;
amino, amino C1-C6 alkyl, CI-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof.
Iri a particular embodiment, R2 is hydroxyl, carboxyl, formyl, carboxy C1-C6 alkyl, carboxy CI-C6 alkoxy, dicarboxy C1-C6 alkyl, dicarboxy C1-C6 alkyloxy, dicarboxyhalo C1-C6 alkyl, dicarboxyhalo C1-C6 alkyloxy, phosphono, phosphono C1-C6 alkyl, phosphonohalo C1-C6 alkyl, phosphoryl, phosphoryl CI-C6 alkyl, or phosphoryl Ci-C6 alkoxy. A particular example of R2 is phosphonomethyl.
[0044] In any of the embodiments of the compounds of formula II, R4 and R5 together form a C4-C$ cycloalkyl, particularly cyclohexyl.
[0045] In any of the embodiments of the compounds of formula II, R6 is a CZ-C6 alkenylenyl or C2-C6 alkynylenyl group, which may optionally have a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof.
[0046] In any of the embodiments of the compounds of formula II, R3 is carboxy alkyl, e.g., carboxy methyl.
[0047] A specific example of the compound of formula IIa is:
O
ol CH2-NNHZ
O
HN
O NH O
r-OH
HO P S HO
(IIa) or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
[0048] The term "aryl" as used herein refers to an aromatic moiety such as phenyl, naphthyl, anthracenyl, and biphenyl. The term "heterocyclyl" refers to a 3-7 membered ring comprising one or more heteroatoms such as 0, N, and S, and optionally carbon and/or hydrogen. Examples of heterocyclyl groups include pyridyl, piperidinyl, piperazinyl, pyrazinyl, pyrolyl, pyronyl, pyronyl, tetrahydropyranyl, tetrahydrothiopyranyl, pyrrolidinyl, furanyl, tetrahydrofuranyl, thiophenyl, tetrahydrothiophenyl, purinyl, pyrimidinyl, thiazolyl, thiazolidinyl, thiazolinyl, oxazolyl, tetrazolyl, tetrazinyl, morpholinyl, thiophorpholinyl, quinolinyl, and isoquinolinyl. The aryl and heterocyclyl moieties may be fused, as in aryl heterocyclyl, such as, e.g., indole, isoindole, benzimidazole, quinoline, isoquinolinyl, benzoxazolyl, benzofuranyl, isobenzofuranyl, carbazolyl, benzodioxolyl, and the like. The alkyl; alkoxy, or alkylamino groups can be linear or branched. When an aryl group is substituted with a substituent, e.g., halo, amino, alkyl, hydroxy, or alkoxy, the aromatic ring hydrogen is replaced with the substituent and this can take place in any of the available atoms (e.g., carbon atoms) bearing a hydrogen, e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10-position, taking, for the purpose of illustration, the 1-position as the point of attachment of the aryl group. The term "halo" refers to fluorine, chlorine, bromine, or iodine.
[0049] The present invention further provides a composition comprising a pharmaceutically acceptable carrier and an effective (e.g., therapeutically or prophylactically effective) amount of at least one of the compounds described above. The present invention further provides a method of inhibiting an SH2 domain from binding with a phosphoprotein comprising contacting a sample or substance containing an SH2 domain with a compound of the present invention.
[0050] The present invention discloses the use of above compounds in the manufacture of a medicament for the treatment of a condition that responds to the inhibition of phosphoprotein binding to an SH2 domain of a mammal. The present iinvention further provides the use of the above compounds in medicine. The compounds can find use as an SH2 domain binding inhibitor. Examples of SH2 domain-containing proteins are Grb2, Shp2, and STAT3 proteins.
[0051] The pharmaceutically acceptable (e.g., pharmacologically acceptable) carriers described.herein,. for example, vehicles, adjuvants, excipients, or diluents, arewell known to those who are skilled in the art and'are readily available to the public. It is preferred that the pharmaceutically acceptable carrier be one which is chemically inert to the active compounds and one which has no detrimental side effects or toxicity under the conditions of use.
[0052] , The choice of carrier will be determined in part by the particular active agent, as well as by the particular method used to administer the composition.
Accordingly, there are a wide variety of suitable formulations of the pharmaceutical compositiori of the present invention. The following formulations for oral, aerosol, parenteral, subcutaneous, intravenous, intraarterial, intramuscular, interperitoneal, intrathecal, rectal, and vaginal administration are merely exemplary and are in no way limiting.
[0053] Formulations suitable for oral administration can comprise (a) liquid solutions, such as an effective amount of the compound dissolved in diluents, such as water, saline, or orange juice; (b) capsules, sachets, tablets, lozenges, and troches, each containing a predetermined amount of the active ingredient, as solids or granules; (c) powders; (d) suspensions in an appropriate liquid; and (e) suitable emulsions. Liquid formulations can include diluents, such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent, or emulsifying agent. Capsule forms can be of the ordinary hard-or soft-shelled gelatin type containing, for example, surfactants;
lubricants, and inert fillers, such as lactose, sucrose, calcium phosphate, and cornstarch. Tablet forms can include one or more of lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, acacia, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, disintegrating agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible carriers. Lozenge forms can compri~e the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredierit in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the active ingredient, such carriers as are known in the art.
[0054] The compounds of the present invention, alone or in combination with other suitable components can be made into aerosol formulations to be administered via inhalation. These aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.
They also can be formulated as pharmaceuticals for non-pressured preparations, such as in a nebulizer or an atomizer.
[0055] Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The compound can be administered in a physiologically acceptable diluent in a pharmaceutical carrier, such as a sterile liquid or mixture of liquids, including water, saline, aqueous dextrose and related sugar solutions, an alcohol, such as ethanol, isopropanol, or hexadecyl alcohol, glycols, such as propylene glycol or polyethylene glycol, glycerol ketals, such as 2,2-dimethyl-1,3-dioxolane-4-methanol, ethers, such as poly(ethyleneglycol) 400, an oil, a fatty acid, a fatty acid ester or glyceride, or an acetylated fatty acid glyceride with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or a detergent, suspending agent, such as pectin, carbomers, methylcellulose, hydroxypropylmethylcellulose, or.
carboxymethylcellulose, or emulsifying agents and other pharmaceutical adjuvants.
[0056] Oils, which can be used in parenteral formulations include petroleum, animal, vegetable, or synthetic oils. Specific examples of oils include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum; and mineral. Suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters. Suitable soaps for use in parenteral formulations include fatty alkali metal, ammonium, and triethanolamine salts, and suitable detergents include (a) cationic detergents such as, for example, dimethyl dialkyl ammonium halides, and alkyl pyridinium halides, (b) anionic detergents such as, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates, (c) nonionic detergents such as, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylene polypropylene copolymers, (d) amphoteric detergents such as, for example, alkyl-(3-aminopropionates, and 2-alkyl-imidazoline quaternary ammonium salts, and (e) mixtures thereof.
[0057] The parenteral formulations will typically contain from about 0.5 to about 25%
by weight of the active ingredient in.solution. Suitable preservatives and buffers can be used in such formulations. In order to minimize or eliminate irritation at the site of injection, such compositions may contain one or more nonionic surfactants. The quantity of surfactant in such formulations typically ranges from about 5 to about 15%
byweight.
Suitable surfactants include polyethylene sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol. The parenteral formulations can be presented in unit-dose or multi=dose sealed cointainers, such as ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
[0058] The compounds of the present invention may be made into injectable formiilations. The requirements for effective pharmaceutical carriers for injectable compositions are well known to those of ordinary skill in the art; see, e.g., Pharmaceutics and Phaf-inacy Practice, J.B. Lippincott Co., Philadelphia, PA, Banker and Chalmers, eds., pages 238-250 (1982), and ASHP Handbook on Ir jectable Drugs, Toissel, 4i' ed., pages 622-630 (1986).
[0059] Additionally, the compounds of the present invention may be made into suppositories by mixing with a variety of bases, such as emulsifying bases or water-soluble bases. Forrnulations suitable for vaginal administration may be presented as pessaries, tampons; creams, gels, pastes, foams, or spray formulas containing, in addition to the active ingredient, such carriers as are known in the art to be appropriate. Suitable doses and dosage regimens can be determined by conventional range-finding techniques known to those of ordinary skill in the art. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired. In proper doses and with suitable administration of certain compounds, the present invention provides for a wide range of responses. Typically the dosages range from about 0.001 to about 1000 mg/kg body weight of the animal being treated/day.
Preferred dosages range from about 0.01 to about 10 mg/kg body weightlday, and further preferred dosages range from about 0.01 to about 1 mg/kg body weight/day.
[0060] Embodiments of the compounds have the advantage that they are stable to or in presence of enzymes encountered during in vivo use. Embodiments of the compounds can find use in in vitro and in vivo applications. For example, the compounds can find use as molecular probes as well as in assays to identify, isolate, and/or quantitate receptor or binding sites in a cell or tissue. The compounds also can find use in vivo for studying the efficacy in the treatment of various diseases or conditions involving SH2 domains.
[0061] The present invention further provides a method of preventing or treating a disease, state, or condition in a mammal by the use of the compounds of the present invention. In an embodiment, the method involves preventing a disease, state, or condition.
In another embodiment, the method involves treating an existing disease, state, or condition.
[0062] In an embodiment, the method involves inhibition of SH2 domain binding with a phosphoprotein. The SH2 domain may involve one or more of the following proteins:
Shp2; STAT3, Src, Lck, Eps, ras GTPase-activating protein (GAP), phospholipase C, PI-3 kinase, Fyn, Lyk, Fgr, Fes, ZAP-70, Sem-5, p85, SHPTP1, SHPTP2, corkscrew, Syk, Lyn, Yes, Hck, Dsrc, Tec, Atk/Bpk, Itk/Tsk,Arg, Csk, tensin, Vav, Emt, Grb2, BCR-Abl, Shc, Nek, Crk, CrkL, Syp, Blk, 113TF, 91TF, and Tyk2, especially Grb2, Shp2, and STAT3.
[0063] Grb2 is an adaptor protein with N- and C-terminal src homology 3 (SH3) domains and a central src homology 2 (SH2) domain. The SH2 domain can bind to phosphoTyr residues of receptors or other adaptor proteins, such as SHC. The domains bind the Ras exchange factor SOS, but can also bind to other adaptor proteins such as GAB 1' and GAB2. Thus, Grb2 is involved in activation of Ras but can also play a role in other signaling pathways in mammalian cells.
[0064] Shp2 is a tyrosine phosphatase that is recruited into tyrosine kinase signaling pathways through binding of its two amino-terminal SH2 domains to specific phosphotyrosine motifs. Shp2 is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules -that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and onc genic transformation. Shp2 contains two tandem Src homology-2 domains, which, function as phosphotyrosine binding domains and mediate the interaction with its substrates. Shp2 is widely expressed in most tissues arid plays a regulatory role in various cell-signaling events that are important for a diversity of cell functions, such as mitogenic activation, metabolic control, transcription regulation, and cell migration, [0065] Signal Transducers and Activators of Transcription (STATs) are transcription factors that are phosphorylated by JAK kinases in response to cytokine activation of a cell surface receptor tyrosine kinases. Upon activation, the STATs dimerize and are localized to the nucleus where they activate transcription of cytokine-responsive genes.
There are at least three JAK kinases and at least six STAT proteins involved in this complex signaling pathway. Cytokines that activate STAT3 include growth hormone, IL-6 family cytokines, and G-CSF. STAT3 induces progression through the cell cycle, prevents apoptosis and upregulates oncogenes, such as c-myc and bcl-X and may play a role in oncogenesis.
STAT3 has been shown to play a critical role in hematopoiesis. The importance of STAT3 is underscored by the failure of mice lacking STAT3 to survive embryogenesis.
Crosstalk from pathways other than JAK kinases also leads to phosphorylation and activation of STAT3 as indicated by a role of mTOR (mammalian target of rapamycin, or p70 S6 kinase) and IVIAP'kinase'pathways in STAT3 activation and signaling.
[0066] The method of treatment or prevention of a diseases comprises administering to the mammal one or more compounds of the present invention. The disease, state, condition can be a cancer, e.g., a breast cancer or an ovarian cancer, or a tumor such as a solid tumor, e.g., a brain tumor, a prostate tumor, and the like, leukemia including chronic myelocytic leukemia, lymphoma, an autoimmune disease, an inflammatory disease, a metabolic disease, diabetes, obesity, or cardiovascular disease.
[0067] The present invention farther provides a method of enhancing the therapeutic effect of a treatment rendered to a mammal comprising administering a compound in conjunction with the treatment. By conjunction, it is meant that the inhibitor can be used in any suitable manner, for example, prior to, simultaneous with, or post-administration of the therapeutic agent. Synergistic effects are observed when the SH2 domain binding inhibitor is used in combination with other treatments known to those skilled in the art. The inhibitor enhances the cytotoxicity of the cheinotherapeutic treatments. Cancer treatment is particularly suitable for this combination treatment.
[0068] ' The cancer may involve any number of mechanisms. A majority of human breast cancers are dependent upon activation of the Ras signaling pathways through activation of growth factor receptot as the means to achieve continuous cellular proliferation. For example, the cancer may involve overexpression of Her-2/neu. The cancer can be mediated through BCIZ-Abl or the expression of erbB-2 receptor.
In cells transformed by p185 erbB-2 overexpression, therapeutic agents affectirig Grb2 function at its SH2 domain may interrupt the flow of signal transduction to the Ras pathway and thus result in reversal of the cancer phenotype.
[0069] The therapeutic treatment can include chemotherapy, radiation therapy, and/or a biological therapy. Examples of chemotherapy include the use of cancer treatment agents such as alkylating agents, hormonal agents, antimetabolites, natural p'roducts,.and miscellaneous agents. Particular examples of cancer treatment agents include paclitaxel, 5-fluoruracil, and doxorubicin. Examples of biological therapy include the use of a protein such as an antibody (monoclonal or polyclonal) or a recombinant protein. An example of an antibody is herceptin, which is targeted for inhibiting the erbB-2 receptor. In embodiments, the enhancement of the therapeutic effect comprises blocking of a cell survival factor in the mammal and/or triggering, e.g., enhancing or speeding up, of cell apoptosis. The treatment can be carried out in vivo, and/or in vitro.
[0070] , The Grb2 SH2 binding inhibitors are effective in inhibiting the association or binding of Grb2 with activated receptor PTKs. Interaction of native Grb2 protein with phosphotyrosinylated proteins including receptor PTKs can be monitored by immunoprecipitating Grb2 and detecting the amount of phosphotyrosinylated proteins which are coprecipitated using anti-phosphotyrosine Western Blotting.
[0071] The compounds of the present invention can be prepared by any,suitable method, for example, a method that advantageously utilizes C-terminal allylglycine amides, for example, compound 1 in Figure 1 in a method involving ring closing metathesis (RCM) reaction of allylglycines onto a(3-vinyl-containing residue;. see, e.g., Figures 1 -3. For examples of RCM reactions, see, Gao et al., Org. Lett. 2001, 3, 1617-1620;
Reichwein et al., Angew. Clzem., Int. Ed. 1999, 38, 3684-3687, J. Org. Chem., 2000, 65, 6187-6195; and J. Org. Chem., 2000, 65, 2335-2344; Stymiest et al., Org. Lett., 2003; 5, 47-49; Miller et al., J. Am. Chem. Soc., 1995, 117, 5855-5856; and Dekker et al., Org. Biomol.
Chem., 2003, 1, 3297-3303. The RCM reaction advantageously allows ring closure with retention of desired functional groups, e.g., phenylphosphate functionality or the chemical (e.g., a lipophile comprising a carbonyl group) functionality at or near the site of ring juncture(s). L- and D-allylglycines and many of the required terminal amines may be commercially available, thereby making the synthesis more readily accessible than certain other methods, for example, those involving the use of C-terminal2-allyl-3-aryl-l-propanamides that lacked the a-carboxyl portion of allylglycine residues. In addition to solution chemistries, the preparation of multiple analogues may be made possible through the use of solid-phase chemistries.
[0072] The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope.
[0073] This example demonstrates a method of preparing compounds in accordance with an embodiment of the invention.
[0074] Reactions were carried out under argon. Anhydrous solvents were purchased from Aldrich Chemical Corporation and used without further drying. Combustion analyses were obtained from Atlantic Microlab, Inc., Norcross, GA. 1H NMR spectra were obtained using a Varian 400 MHz spectrometer and are reported in ppm relative to TMS
and referenced to the solvent in which they were run. Fast atom bombardment mass spectra (FABMS) were acquired with a VG analytical 7070E mass spectrometer. HPLC
separations were conducted using a. Waters Prep LC4000 system with photodiode array detection and either a J-sphere ODS-H80 column (20 x 250 mm) with a solvent system consisting of 0.1 % aqueous TFA (v/v, solvent A) / 0.1 % TFA in MeCN (v/v, solvent B).
[0075] N-Boc-L-A11y1Gly-(1-naphthyl)methyl amide (5a). An ice-cold solution of N-Boc L-allylglycine=dicyclohexylamine salt (Fluka).(1.61 g, 4.05 mmol) in 0.1 N
HCl (100 mL) was extracted with ice-cold EtOAc (3 x 50 mL) and the combined extracts were dried (Na2SO4) and taken to dryness to yield the free amine as a syrup (898 mg). To a solution of this syrup in anhydrous DMF (9 mL) was added 1-hydroxybenzotriazole=H2O.(HOBt) (601 mg, 4.46 mmol) and 1,3-diisopropylcarbodiimide (DIPCDI) (696 L, 4.46 mmol) and after minutes, (1-naphthyl) methylamine (653 L, 4.46 mmol) and the resulting mixture was stirred at room temperature overnight. The mixture was taken to dryriess under high vacuum at 50 C and the resulting syrup was dissolved in EtOAc and purified by silica gel flash chromatography (hexanes in EtOAc) to yield product 5a as cream-colored crystals (1.15 g, 80% yield). H NMR (CDC13) S 1.31 (s, 9 H), 2.44 - 2.53 (m, 2 H), 4.08 - 4.16 (m, 1 H), 4.81 - 4.94 (m, 2 H), 5.04 - 5.12 (m, 2 H), 5.64 - 5.78 (m, 1 H), 6.32 -6.38 (br m, 1 H), 7.39 (dd, J= 7.0 and 10.7 Hz, 1 H), 7.46 (dd, J= 1.5 and 6.8 Hz, 1 H), 7.49 (dd, J= 1.3 and 2.1 Hz, 1 H), 7.59 (dd, J= 1.6 and 7.8 Hz, 1 H), 7.77 - 7.80 (br-m, 1H), 7.83 -7.86 (br-m, 1 H), 7.94 (br-d, J= 8.0 Hz, 1 H). FAMBS m/z 355.2 (MH).
[0076] N-Boc-D-Al1ylGly-(1-naphthyl)methyl amide (5b). Treatinent of N-Boc-D-allylglycine=dicyclohexylamine salt (PepTech) (2.72 g. 6.86 mmol) in a manner similar to that used to prepare 5a, provided product 5b as a light yellow solid in quantitative yield. H
NMR: refer to that provided for enantiomeric 5a. FABMS m/z 355.1 (MH+).
[0077] N-Fmoc-L-Asn-L-A11y1Gly-(1-naphthyl)methyl amide (6a). A solution of 5a (254 mg, .1.00 mmol) in TFA: H20 (9:1) (10 mL) was stirred at room'temperature (1 h), then TFA was removed by rotary evaporation under reduced pressure and the residue was partitioned between saturated NaHCO3 in brine (25 mL) and EtOAc (2 x 25 mL).
The organic extract was dried (Na2SO4); evaporated to an oil (203 mg), taken up in DMF (1 mL) and to this was added an HOBt active ester solution prepared by reacting N-Fmoc-L-asparagine (Novabiochem) (357 mg, 1.10 mmol), HOBt (148 mg, 1.10 mmol) and DIPCIDI
(172 L, 1.10 mmol) in DMF (3 mL), 15 minutes. The resulting clear solution was stirred at room temperature to rapidly yield a thick white suspension. The suspension was diluted with DMF (4 mL) and stirring was continued at room temperature (overnight).
Solvent was removed at 50 C under high vacuum aind the residue was triturated well with MeOH (10 mL), collected by filtration and washed well with MeOH to yield product 6a as a snow-white solid (424 mg, 72% yield). H NMR (DMSO-d6) S 2.24 - 2.56 (m, 4 H), 4.14 -4.20 (m, 3 H), 4.24 - 3.36 (m, 2 HO, 4.66 (d, J= 6.9 Hz, 2 H), 4.89 (br-d, J= 10.4 Hz, 1 H), 4.98 (br-d, J= 17.2 Hz, 1 H), 5.61 - 5.72,(m, 1 H), 6.90 .(br-s, 1 H), 7.24 - 7.40 (m; 8 H), 7.44 -7.50 (m, 2 H), 7.57 (d, J= 8.0 Hz, 1 H), 7.64 (d, J= 5.8 Hz, 2 H), 7.78 = 7.79 (m, 1 H), 7.84 (d, J= 7.5 Hz, 2 H), 7.87 -7.90 (m, 1 H), 8.00 (br-t, J, J= 6.1 Hz, 2 H), 8.46 (br-t, J= 5.6 Hz, 1 H). FABMS m/z 591.3 (MH)+.
[0078] N-Fmoc-L-Asn-D-AllylGly-(1-naphthyl)methyl amide (6b). Treatment of 5b (1.64 g, 6.45 mmol) in a manner similar to that used to prepare 6a from 5a, provided product 6b as white foam in quantitative yield. H NMR (DMSO-d6) 6 2.24 - 2.43 (m, 4 H), 4.06 - 4.14 (m, 3H), 4.25 - 4.34 (m; 2 H), 4.65 (d, J= 5.8 Hz, 2 H), 4.90 (br-d, J= 9.6 Hz, 1 H), 4.98 (br-d, J= 17.5 Hz, 1 H), 5.58 - 5.70 (m, 1 H), 6.89 (br-s, 1 H), 7.24 (dd, J= 7.4 and 15.0Hz,2H),7.30-7.38(m,5H);7.44-7.48(m,2H),7.56(br-d,J=7.6Hz, 1 H), 7.60 (br-t, J= 6.5 Hz, 2 H), 7.75 (br-d, J= 8.0 Hz, 1 H), 7.82 - 7.88 (m, 3 H), 7.96 - 7.99 (m, 1 H), 8.05 (d, J= 8.4 8.4 Hz, 1 H). FABMS fn/z 591.3 (MH)+.
[0079] H-L-Asn-L-A1lylGly-(1-naphthyl)methyl amide (7a). To a suspension of 6a (1.11 g, 1.88 mmol) in DMF (10 mL) was added piperidine (15 equivalents) and the mixture was stirred at room temperature (2 h). Solvent and piperidine were removed under high vacuum to yield a white solid, which was dissolved in MeOH: EtOAc and purified by silica gel flash chromatography (MeOH: EtOAc) to yield free amine 6a as a gel that became a white solid on prolonged exposure to vacuum (540 mg, 78% yield). H NMR (DMSO-d6) S
2.12 - 2.46 (m, 4 H), 3.44 (dd, J= 5.7 and 8.6 Hz, 1 H), 4.30 (br-s, 1 H), 4.63 - 4.53 (m, 2 H), 4:95 (dd, J==2.1 and 10.1 Hz, 1.H), 5.01 (dd, J- 2.1 and 17.2 Hz, 1 H)x 5..61 - 5.72 (m, 1 H), 6.82 (br-s, 1 H), 7.34 - 7.44 (m., 3 H), 7.46 - 7.52 (m, 3 H), 7.79 (br-d, J= 7.6 H, 1 H), 7.87 - 7.92 (m, 1 H), 7.98 - 8.02 (m, 1 H), 8.11 (br-s, 1 H), 8.52 (t, J= 5.9 Hz, 1 H).
FABMS nz/z 369.2 (MH)+.
[0080] N-Fmoc-Ac6c-L-Asn-L-AllylGly-(1-naphthyl)methyl amide (8a). To a solution of amine 7a (368 mg, 1.00 mmol) in DMF (3 mL) was added an HOBt active ester solution prepared by reacting N-Fmoc- 1 -aminocyclohexane carboxylic acid (N-Fmoc-Ac6c-OH) (Advanced ChemTech) (420 mg, 1.10 mmol),'HOBt (148 mg; 1.10 mrmol) and DIPCIDI (172 L, 1.10 mmol) in DMF (3 mL), 10 minutes and the resulting solution was stirred at room temperature (overnight). The reaction mixture was taken to dryness under high vacuum and purified by silica gel flash chromatography (MeOH: EtOAc) to yield product 8a as white foam in quantitative yield. H NMR (CDC13) 8 1.10 - 1.82 (m, 10 H), 2.38 - 2.56 (m, 2 H), 2.73 - 2.79 (m, 2 H), 4.02 - 4.23 (m, 3 H), 4.35 - 4.45 (m, 2 H), 4.62 (dd, J= 4.7 and 14.8 Hz, 1 H), 4.87 (dd, J= 1.7 and 10.3 Hz, 1 H), 4.94 - 5.01 (m, 2 H), 5.58 - 5.75 (m, 1 H), 6.82 (s, 1 H), 7.18 - 7.39 (m, 9 H), 7.40 -7.42 (m, 1 H), 7.46 - 7.48 (m, 1 H), 7.61 - 7.64 (m, 2 H), 7.68 - 7.74 (m, 3 H), 7.92 (d, J= 8.6 Hz, 1 H), 7.96 (s, 1 H), 8.27 (d, J= 5.7 Hz, 1 H). FABMS m/z 716.2 (MH)+.
[0081] N-Boc-Ac6c-L-Asn-D-A11y1Gly-(1-naphthyl)methyl amide (8b). Protected peptide 6b (300 mg, 0.507 mmol) was treated with 20% Et2NH in DMF (5 mL) for minutes at room temperature. Concentration under reduced pressure gave the corresponding crude amine. To a stirred solution of the amine in dry DMF (1 mL) and 1-hydroxy-,7-azabenzotriazole (HOAt) in DMF (0.5 M, 1.11 mL, 0.558 mmol) were added N-Boc-Ac6c-OH (135 mg, 0.558 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide=HCl (EDCI=HCI) (116 mg, 0.609 mmol), and the mixture was stirred for 12 h at room temperature. The mixture was extracted with EtOAc, and the extract was washed successively with 5% citric acid solution, brine, 5% aqueous NaHCO3 and brine, and dried -over Na2SO4. Concentration followed by, flash chromatography over silica gel using CH2C12-MeOH (95:5) provided product 8b as colorless solid (84 mg, 28%
yield). 1H-NMR (400 MHz, CDC13) 6 1.25 (m, 2 H), 1.40 (s, 9 H), 1.63 (m, 6 H), 1.84 (m, 1 H), 2.03 (m, 1 H), 2.39 (dd, J= 16.5 and 4.2 Hz, 1 H), 2.54 (ddd, J= 14.6, 10.7 and 7.7 Hz, 1 H), 2.88 (m, 1 H), 2.94 (dd, J= 16.5 and 4.9 Hz, 1 H), 4.32 (br, 1 H), 4.45 (m, 1 H), 4.58 (m, 2 H), 4.90 (s, 1 H), 5.05 (m, 2 H), 5.15 (dd, J= 16.9 and 1.6 Hz, 1 H), 5.35 (br, 1 H), 5.79 (m, 1 H), 7.16 (m, 1 H), 7.41 (m, 2 H), 7.49 (m, 2 H), 7.68 (d, J= 8.8 Hz; 1 H), 7.74 (m, 2 H), 7.81 (d, J= 7.9 Hz, 1 H), 8.00 (d, J= 8.6 Hz, 1 H). FABMS nz/z 594 (MH) [0082] = H-Ac6c-L-Asn-L-A11y1Gly-(1-naphthyl)methyl amide (9a). To a solution of 8a (738 mg, 1.00 mmol) in DMF (5 mL) was added piperidine (1.0 mL, 10 mmol) and the solution was stirred at room temperature (40 minutes). Solvent was then removed under high vacuum at 50 C and the resulting residue was purified by silica gel flash chromatography (MeOH: EtOAc) to provide an oil. Lyophilization from dioxane provided product 9a as a white solid (343 mg; 84% yield). FABMS m/z 494.3. (MH+). ' [0083] H-Ac6c-L-Asn-D-A11y1Gly-(1-naphthyl)methyl amide (9b). Preparation of peptide 9b by solid-phase methods is outlined below.
[0084] [(2R,3R)-3-(4-Di-tert-butyloxyphosphonomethyl)phenyl-2-(tert=
butyloxycarbonylmethyl)pent-4-enyl]-Ac6c-L-Asn-L-A11y1Gly-(1-naphthyl)methyl amide (lla). To a stirred solution of 9a (70 mg, 0.141 mmol) in dry DMF (0.30 mL) and HOAt in DMF (0.5 M, 0.311 mL, 0.155 mmol) were added protected'pTyr mimetic 10 (77 mg, 0.155 mmol; Wei et al., J. Med. Claem. 2003, 46, 244-254) and EDCI-HCI (32 mg, 0.170 mmol), and the mixture was stirred for 12 h at 50 C. The mixture was extracted with EtOAc, and the extract was washed successively with saturated citric acid solution, brine, 5% aqueous NaHCO3 solution and brine, and dried over Na2SO4.
Concentration followed by flash chromatography over silica gel using CHZC12: MeOH (95:5) provided lla as colorless solid (16 mg, 12% yield). 1H-NMR (400 MHz, CDC13) 8'0.72 - 1.62 (m, 37 H), 2.47 (m, 2 H), 2.62 (m, 3 H), 2.82 (m, 1 H), 2.96 (d, J= 21.5 Hz, 2-H), 3.02 (m, 1 H), 3.51 (m, 1 H); 4.31 (m, 1 H), 4.44 (m, 1 H), 4.83 (dd, J= 15.0 and 5.3 Hz, 1 H), 4.97 (dd, J=
15.0 and 6.0 Hz, 1 H), 5.05 (m, 3 H), 5.15 (dd, J= 17.1 and 1.6 Hz, 1 H), 5.25 (br, 1 H), 5.69 (m, 1 H), 5.81 (m, 1 H), 6.22 (s, 1 H), 6.71 (br, 1 H), 7.11 - 7.25 (m, 5 H), 7.35 - 7.55 (m, 5 H), 7.59 (d, J= 8.3 Hz, 1 H), 7.72 (d, J= 8.1 Hz, 1 H), 7.81 (d, J= 9.2 Hz, 1 H), 8.04 (d, J= 8.1 Hz, 1 H). FABMS m/z 972 (MH)+.
[0085] [(2R,3R)-3-(4-Di-tert-butyloxyphosphonomethyl)phenyl-2-(tert-butyloxycarbonylmethyl)pent-4-enyl]-Ac6c-L-Asn-D-A11y1Gly-(1-naphthyl)methyl amine (llb). Protected peptide 8b (70.mg, 0.117 mmol) was treated with TFA:
anisole (10:1, 5.5 mL) for 2 h at room temperature. Concentration under reduced pressure gave the corresponding amine 9b as its TFA salt. To a stirred solution of the amine 9b in dry DMF
(0.300 mL) and HOAt in DMF (0.5 M, 0.259 mL, 0.129 mmol) were added protected pTyr mimetic 10 (64 mg, 0.129 mmol), EDCI=HC1(27 mg, 0.141 mmol) and i-Pr2NEt (0.040 mL, 0.234 mmol) at 0 C, and stirring was continued for 24 h at 50 C., The mixture was extracted with EtOAc, and the extract was washed successively with saturated citric acid solution, brine, saturated aqueous NaHCO3 solution and brine, and dried over Na2SO4.
Concentration followed by flash chromatography over silica gel using CHZC12:
MeOH
(95:5) provided llb as colorless solid (52 mg, 45% yield). 1H-NMR (400 MHz, CDC13) 6 0.78 - 1.66 (m, 37 H), 2.51 - 2.73 (m, 4 H), 2.80 (m, 1 H), 2.88 - 3.05, (m, 4 H), 3.32 (t, J=
10.0 Hz, 1 H), 4.11 (m, 1 H), 4.52 (m, 1 H), 4.77 (dd, J= 15.5 and 5.1 Hz, 1 H), 4.99 - 5.23 (m, 6 H),, 5.70 - 5.99 (m, 4 H), 7.06 (m, 2 H), 7.20 (m, 2 H), 7.37 (m, 1 H), 7.43 - 7.61 (m, 6 H), 7.72 (d, J= 8.1 Hz, 1 H), 7.82 (m, I H), 8.04 (d, J= 8.3 Hz, 1 H). FABMS
nzlz 972 (MH)+.
[0086] Cyclo{[(2R,3R)-3-(4-di-tert-butyloxyphosphonomethyl)phenyl-2-(tert-butyloxycarbonylmethyl)pent-4-enyl]-Ac6c-L-Asn-L-AIlylGly}-(1-naphthyl)methyl amide (12a). To a solution of lla (15 mg, 0.015 mmol) in CHZC12 (3.7 mL) was added 2nd generation Grubbs RCM catalyst, [1;3-bis-(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(phenylmethylene)-(tricyclohexylphosphine)ruthenium]
[((PCy3)(Im(Mes)2)Ru=CHPh)] (Aldrich) (6.5 mg, 0.0077 mmol) in CH2C12 (1.3 mL) under argon. The reaction mixture was stirred at 45 C for 24 h. The crude reaction mixture was evaporated in vacuo and the residue was purified by silica gel chromatography using CH2C12: MeOH (10:1) to provide 12a as colorless powder (11 mg, 73% yield). 'H-NMR
(400 MHz, CDC13) S 1.16 - 1.58 (m, 30 H), 1.61 (m, 1 H), 1.72 (rn, 1 H), 1.89 (m, 4 H), 2.07 (m, 1 H), 2.35 (m, 1 H), 2.46 - 2.73 (m, 4 H), 2.99 (m, 3 H), 3.57 (m, 1 H), 3.88 (m, 1 H), 4.83 (m, 2 H), 4.90 (m, 1 H), 5.13 (m, 2 H), 5.83 (dd, J= 15.3 and 7.6 Hz, 1 H), 6.24 (br, 1 H), 7.08 (m, 1 H), 7.11 - 7.25 (m, 4 H), 7.34 - 7.56 (m, 4 H), 7.68 (m, 1 H), 7.73 (d, J
= 8.3 Hz, 1 H), 7.84 (d, J= 7.8 Hz, 1 H), 7.98 (d, J= 8.8 Hz, 1 H), 8.03 (d, J= 8.3 Hz, 1 H).
FABMS mlz 944 (MH)+. , [0087] Cyc1o{[(2R,3R)-3-(4-di-tert-butyloxyphosphonomethyl)phenyl-2-(tert-butyloxycarbonylmethyl)pent-4-enyl]-Ac6c-L-Asn-D-A11y1Gly}-(1-iiaphthyl)methyl amide (12b). To a solution of llb (55 mg, 0.057 mmol) in CH2C12 (25 mL) was added [((PCy3)(Im(Mes)2)Ru=CHPh)] (27 mg, 0.032 mmol) in CH2C12 (8 mL) under argon and the reaction mixture was stirred at 45 C (48 h). The crude reaction mixture was then evaporated in vacuo, and residue was purified by silica gel flash chromatography to provide 12b as yellow oil (28 mg, 52% yield). 'H NMR (CDC13) S 8.04 (m, 1H), 7.87 (d, 1H, J=
8.5 Hz), 7.83 (m, 1H), 7.75 (d, 1 H, J= 8.3 Hz), 7.54-7.40 (m, 6H), 7.24 (dd, 2H, J= 2.4 Hz & 8.3 Hz), 7.14 (d, 2H, J= 7.9 Hz), 6.81 (d, 1 H, J= 7.5 Hz), 5.98 (s, 1 H), 5.81 (dd, 1 H, J
9.1 Hz & 15.5 Hz), 5.72 (s, 1 H), 5.40 (m, 1 H), 5.02 (m, 1 H), 4.79 (dd, 1H, J=. 5.0 Hz &
14.9 Hz), 4.57 (m, 1H), 4.48 (m, 1H), 3.54 (m, 1H), 3.06 (m, 1H), 3.02 (d, 2H, J= 21.5 Hz), 2.97 (m, 1H), 2.88 (dd, 1H, J= 5.6 Hz & 15.9 Hz), 2.63 (dd, 1H, J= 4.1 Hz &
16.1 Hz), 2.43 (dd, 1H, J= 11.2 Hz & 17.2 Hz), 2.23 (m, 1H), 1.95 (dd, 1H, J- 3.0 Hz &
17.2 Hz), 1.86-1.44 (m, 6H), 1.42 (s, 9H), 1.40 (s, 9H), 1.36 (s, 9H), 1.31-1.20 (m, 4H). FABMS na/z 944 (MH)+.
[0088] Cyclo{[(2R,3R)-3-(4-dihydroxyphosphonomethyl)phenyl-2-(hydroxycarbonylmethyl)pent-4-enyl]-Ac6c-L-Asn-L-AllylGly}-1-naphthyl)methyl amide (3). Protected peptide 12a (10 mg, 0.010 mmol) was treated with TFA: H20 (95:5, 2 mL) for 2 h at room temperature. Concentration followed by preparative HPLC
purification (linear gradient 30 to 40% B in A over 30 minutes).provided 3 as colorless powder (4.6 mg, 56% yield). 'H-NMR (400 MHz, DMSO-d6) b 1.23 (m, 1 H), 1.48 (m, 5 H), 1.78 (m, 4 H), 2.06 (m, 1 H), 2.3 5.(m, 1 H), 2.42 - 2.72 (m, 4 H), 2.92 (d, J= 21.2 Hz, 2 H), 3.21 (m, 1 H), 4.02 (m, 1 H), 4.34 (m, 1 H), 4.58 (in, 1 H), 4.72 (dd, J= 1.5.4 and 5.2 Hz, 1 H), 4.81 (dd, J
= 15.6 and 5.6 Hz, 1 H), 5.34 (m, 1. H), 5.84 (dd, J= 15.2 and 8.0 Hz, 1 H), 6.86 (br, 1 H), 7.06 (d, J= 8.0 Hz, 1 H), 7.18 - 7.29 (m, 4 H), 7.36 (br, 1 H), 7.42 - 7.60 (m, 4 H) 7.70 (d, J= 8.5 Hz, 1 H), 7.83 (d, J= 7.2 Hz, 1 H), 7.94 (d, J= 7.2 Hz, 1 H), 8.06 (d, J= 8.5 Hz, 1 H), 8.16 (s, 1 H), 8.31 (t, J= 5.4 Hz, 1 H). FABMS mlz 774 [(M-H)-].
[0089] - Cyclo{[(2R,3R)-3-(4-dihydroxyphosphonomethyl)phenyl-2-(hydroxycarbonylmethyl)pent-4-enyl]-Ac6c-L-Asn-D-A11y1Gly}-(1-naphthyl)methyl amide (4). A solution of 12b (22 mg, 0.023 mmol) in a mixture of TFA:
triethylsilane (TES): H20 (4.0 mL, v:v, 3.7:0.1:0.2) was stirred at room temperature (1 h).
Solvent was evaporated in vacuo and residue was purified by HPLC using a linear gradient using a linear gradient (5% to 95% B over 15 minutes) provided product 4 as white solid (8.4 mg, 46%
yield). 'H NMR (DMSO-d6) S 8.22 (m, 1H), 8.15 (s, 1H), 8.09 (m, IH), 8.00 (m, 1H), 7.84 (dd, 1 H, J= 2.6 Hz & 6.7 Hz), 7.72 (d, 1 H, J= 6.4 Hz), 7.46-7.3 6 (m, 4H), 7.31 (s, 1 H), 7.12-7.06 (m, 5H), 6.83 (s, 1H), 5.$0 (dd, 1H, J= 9.2 Hz & 15.9 Hz), 5.27 (m, 1H), 4.72-4.64 (m, 2H), 4.56 (m, 1H), 3.91 (m, 1H), 3.81 (m, 1H), 3.16 (m, 1H), 2.69 (d, 2H, J= 20.8 Hz), 2.60-2.50 (m, 3H), 2.25 (m, 1H), 1.84 (m, 1H), 1.78-1.16 (m, 10H). FABMS
fn/z 775 M}, 776 (MH)+.
[0090] . Conversion of 4 to Its Tri-sodium Salt. Compound 4 (5.2 mg, 0.0067 mmol) was dissolved in a solution of acetonitrile: H20 (1.0 mL, v/v = 1:1) and to this solution was added a NaHCO3 solution (0.334 mL, 0.0201 mmol) and the resulting solution was lyophilized to provide the tri-sodium salt of 4 as white solid (5.6 mg, 100%
yield).
[0091] General Procedure for Reductive Amination on Resin. To a suspension of (4-formyl)-3-methoxyphenoxy)butyryl-NovaGel HL resin 13 (55 mg, 0.030 mmol;
Novabiochem, Inc.) in dry 1,2-dichloroethane-trimethyl orthoformate (2:1, 1.2 mL) were added 1-naphthylmethylamine (0.044 mL, 0.30 mmol) and NaBH(OAc)3 (64 mg, 0.30 mmol), and agitation was continued for 12 h at room temperature. The resin was washed successively with DMF, 10% i-Pr2NEt/DMF and DMF to provide 1V-(1-naphthylmethylamino)-modified resin 14.
[0092] General Procedure for the Solid-Phase Synthesis of Protected Peptides on Resin. Protected peptide-resins were manually constructed by Fmoc-based solid-phase peptide synthesis. Trityl was employed for Asn side-chain protection. Fmoc deprotection was achieved by 20% piperidine in DMF (2 x 1 min, 1 x 20 min). Fmoc-amino acids were coupled by treatment with 5 equivalents of Fmoc-amino acid and coupling reagents [HATU/HOAt for Gly and Al1ylGly for 6 h; (DIPCDI)/HOBt for Asn(Trt) for 2 h;
DIPCDI/HOAt for Ac6c for 6 h] in DMF. The pTyr mimetic 10 was coupled using DIPCDI/I4OAt in DMF for 2 days at 50 C.
[0093] [(2R)-3-(4-Dihydroxyphosphonomethyl)phenyl-2-(hydroXycarbonylmethyl) propionyl]-Ac6c-L-Asn-Gly-(1-naphthyl)methyl Amide (2). Protected peptide resin 16 (87 mg, 0.030 nunol) resulting from elaboration of modified resin 14 using the appropriate amino acids as described above under general procedures for solid-phase synthesis, was treated with TFA: H20 (95:5, 10 mL) for 2 h at room temperature. After removal of resin by filtration, the filtrate was concentrated and purified by preparative'(linear gradient from 30 to 40% B in A over 30 min) to provide 2 as colorless powder (10 mg, 45%,yield based on resin substitution). 1H-NMR (400 MHz, DMSO-d6) S 1.00 - 1.29 (m, 2 H), 1.29 - 1.63 (m, 6 H), 1.82 (m, 2 H), 2.04 (dd, J= 16.6 and 3.9 Hz, 1 H), 2.43 - 2.65 (m, 4 H), 2.90 (d, J
= 21.3 Hz, 2 H), 2.96 (m, 1 H), 3.11 (m, 1 H), 3.68 (dd, J= 16.9 and 5.7 Hz, 1 H), 3.83 (dd, J= 16.9 and 6.4 Hz, 1 H), 4.34 (dt, J= 7.4 and 5.7 Hz, 2 H), 4.73 (m, 2 H), 6.91 (br, 1 H), 7.09 - 7.19 (m, 4 H), 7.42 (m, 3 H), 7.54 (m, 2 H), 7.73 (d, J= 7.4 Hz, 1 H);
7.81 (m, 1 H), 7.90 - 8.00 (m, 2 H), 8.06 (m, 1 H), 8.11 (t, J= 5.7 Hz, 1 H), 8.28 (s, 1 H).
FABMS rnlz 736 [(M-H)"].
[0094] H-Ac6c-L-Asn-n-A11y1Gly-(1-naphthyl)methyl amide (9b). Protected peptide resin 15c (429 mg, 0.15 mmol), resulting from elaboration of modified resin 14 using the appropriate amino acids as described above under general procedures for solid-phase synthesis, was treated with TFA: H20 (95:5, 10 mL) for 2 h at room temperature. After filtration, the filtrate was concentrated and neutralized with saturated NaHCO3 solution.
The whole was extracted with EtOAc, and the extract was washed with brine, and dried over Na2SO4. Concentration followed by silica gel flash chromatography using EtOAc:
MeOH (8:2) provided 9b (74 mg, quant.) as colorless solid. 1H-NMR (400 MHz, DMSO-d6) 8 1.13 (m, 1 H), 1.27 (m, 2 H), 1.36 - 1.57 (m, 5 H), 1.66 (m, 2 H), 2.34 (m, 1 H), 2.40 -2.58 (m, 3 H), 4.31 (m, 1 H), 4.45 (m, 1 H), 4.74 (d, J= 5.8 Hz, 2 H)y 4.98 (d, J= 10.2 Hz, 1 H), 5.04 (d, J 17.2 and 1.6 Hz,.1'H), 5.69 (m, 1-H), 6.95 (br, 1 H), 7.45 (m, 3 H), 7.54 (m, 2 H),, 7.84 (dd, J= 7.0 and 2.3 Hz, 1 H), 7.92 (m, 2 H), 8.06 (m, 1 H), 8.48 (m, 2 H).
FABMS m/z 494 (MH+).
[0095] Preparation of 15a, 15b, 17a, 17b, 18a, and 18b. As illustrated iri Figure 3, elaboration of resin 14 by coupling with either N-Fmoc L-allylglycine or N-Fmoc D-allylglycine gave resins 15a and 15b, respectively. Coupling of Asn and Ac6c residues followed by pTyr mimetic 10 yielded resins 17a and 17b, respectively. HPLC
analysis of small samples of cleaved resin provided single major peaks that gave MALDI
mass spectra consistent with the structure of peptides 18a and 18b, respectively. This indicated that the coupling of pTyr mimetic 10 had been achieved satisfactorily. Peptides 18a and 18b may be converted to compounds 3 and 4, respectively, by an RCM reaction.
[0096] Preparation of 20: 1-Chloro-l-cyanocyclohexane (J. Org. Chem. 1968, 33, 2211 '- 2214). To a solution of phosphorus pentachloride (66.8. g, 0.32 mol) and pyridine (34 mL, 0.42 mol) in chloroform (300 mL, HPLC grade), was added cycanocyclohexane 19 (25 mL, 0.21 mol), the mixture was heated to reflux overnight. The reaction mixture was cooled to r.t., poured into crashed ice carefully, and the aqueous phase was extracted by ether (200 mL x 2), the combined organic phase was washed by water (200 mL x 3), sat.
NaHCO3 (100 mL), brine (100 mL), dried over anhydrous Na2SO4, after concentrated, the residue oil was distilled to afford 20 as a colorless liquid 28.6 in 95%
yield. 73 C/4 mmHg;
1H NMR (CDC13) S 2.33 (2 H, m), 2~.00 (2 H, m), 1.83 (2 H, m), 1.751-1.61 (3 H, m), 1.40 (1 H, m); 13C NMR (CDC13) 5 119.5; 57.3, 40.2, 24.0, 23.2.
[0097] Preparation of 21 (Org. Lett. 2004, 6, 501- 503): To a solution of 20 (5.0 g, 34.8 mmol) and allyl bromide (3.25 mL, 38.3 mmol) in dry THF (150 mL) at- 78 C, was added n-BuLi (2.5 M, 15.3 mL, 38.3 mmol); the mixture was stirred at- 78 C for 2 hours before sat. NH4C1(30 mL) was added. The mixture was extracted with ethyl acetate, washed with brine, dried over anhydrous Na2SO4, purified by column (silica gel, hexane and ethyl acetate) to afford 21 as a pale yellow oi13.8 g in 76% yield. 'H NMR
(CDC13) 6 5.90 (1 H, m), 5.20 (2 H, m), 2.30 (2 H, m), 2.00 (2 H, m), 1.85 - 1.50 (6 H, m), 1.25 (2 H, m); 13C NMR (CDC13) S 131.9, 123.0, 119.6, 44.6, 35.3, 25.3, 22.9.
[0098] Preparation of 22. To a solution of C (3.80 g, 25.5 mrriol) in dry ether ( 200 mL) at 0 C, was added LiAlH4 (2.0 g, 52.6 mmol) carefully, the mixture was stirred at r.t.
overnight. The reaction mixture was cooled to 0 C before water (5.0 mL) was added carefully, stirred vigorously until the color turned to white, dried over anhydrous Na2SO4, flitered, and the filtrate was concentrated to a colorless oil (free amine, 3.20 g) which was used directly for the next step. To a pre-prepared actived ester solution [Boc-Asn-OH (1.16 g, 5.0'mniol), HOBT (0.70 g, 5.0 mmol), EDCI (1.00 g, 5.0 mmol).and DIPEA
(1.75 mL, 10 mmol) was mixture in dry DCM (25 mL) and stirred at r.t. for 15 mins], free amino (0.75 g, 5.0 nunol) was added, the mixture was stirred at r.t. overnight. Ethyl acetate (200 mL) was added, washed by water and brine, dried over anhydrous Na2SO4, purified by column (silical gel, hexane and ethyl acetate) to afford 22 as a colorless solid 200 mg in 11 % yield over 2 steps. . iH NMR (CDC13) 8 6.94 (1 H, s), 6.29 (1 H, s), 6.20 (1 H, d, J= 6.4 Hz), 5.84 (1 H, m), 5.64 (1 H, s), 5.10 (2 H, m), 4.45 (1 H, m), 3.17 (2 H, in), 2.94.(1 H, dd, J=
15.2, 3.6 Hz), 2.55 (1 H, dd, J= 15.4, 6.2 Hz), 2.03 (2 H, m), 150 -1.20 (19 H, m); FAB-MS (+VE) m/z 368.4 (MH).
[0099] Preparation of 23. To a solution of 22 (47 mg, 0.128 mmol) in DCM (1.50 mL), was added TES (0.32 mL) and TFA (0.80 mL), the mixture was stirred at r.t. for 1.5 hrs. the solvent was removed in vacuo and the residue was used directly. To a solution of pre-prepared actived ester of 25 [a mixtue of 25 (72 mg, 0.116 mmol), HOAT (19 mg, 0.140 mmol), EDCI (28 mg, 0.140 mmol) and DIPEA (91 L, 0.522 mmol) in DMF (4.0 mL) was stirred at r.t. for 15 mins], was added a solution of free amine in DMF (2.0 mL), the mixture was stirred at r.t. for 18 hrs. Ethyl acetate (100 mL) was added to the reaction mixture, washed by water and brine, dried over anhydrous Na2SO4, purified by column'(silica gel, chloroform and methanol) to afford 23 as a colorless solid 60 mg in 60% yield.
(CDC13) 8 7.27 - 7.16 (5 H, m), 7. 10 (1 H, m), 6.67 (1 H, s), 6.00 (1 H, s), 6.00 -5.80(2H, m),5:40(1H,s),5.12-5.05(4H,rn),4.55(1H,m),3.50(1H,t,J14.0Hz),3.25(1H, dd,J=13.2,6.8Hz),3.10-2.95(4H,m),2.83-2.70(2H,m),2.64(2H,m),2.08(2H, m), 1.90 = 1.10 (47 H, m); FAB-MS (+VE) m/z 871.6 (MH}).
[00100] Preparation of 24. The solution of 23 (60 mg, 0.069 mmol) in dichloroethane (35 mL) was degassed for 5 mins under Ar, Grubbs's catalyst II (30 mg) was added, and the mixture was refluxed for 24 hrs. The solvent was removed in vacuo, the residue was purified by column (silical gel, hexane and ethyl acetate); the crude product was treated with TFA (9.5 mL); H20 (0.5 mL) and TES (0.50 mL) at r.t. for 2 hrs, the final product was purified by HPLC, after lyophilized, 24 was got as a white 'power, 8 mg, 17%
yield over 2 steps.1H NMR (CDC13) 8 8.36 (2 14, m), 7.55 (1 H, s) 7.30 (2 H, AB, JAB = 8.0 Hz), 7.19 (2 H, AB, JAB = 8.0 Hz), 7.16 (1 H, s), 6.59 (1 H, m), 5.80 (1 H, dd, J= 15.2, 9.6 Hz), 5.66 (1 H, m), 4.28 (1 H, m), 4.13 (1 H, m), .3.60 (2 H, m) 3.16 (1 H, m), 2.90 (2 H, d; J= 21.2 Hz), 2.77 (2 H, m), 2.36 (1 H, dd, J= 16.0, 4.8 Hz), 2.20 (1 H, m), 2.07 - 1.94 (2 H, m), 1.90 -1.40 (20 H, m); FAB-MS (-VE) rn/z 673.4 (M-H)-.
[00101] This example illustrates a property of compounds in accordance with an embodiment of the invention.
[00102] Biosensor Analysis: Binding experiments were performed on a Biacore instrument (Biacore Inc., Piscataway NJ). All Biotinylated Grb2 SH2 domain proteins (b-Grb2) were expressed and purified (Protein Expression Laboratory and The Protein Chemistry Laboratory, SAIC - Frederick). The b-Grb2 was immobilized onto carboxymethyl 5' dextran surface (CM5 sensor chip, Biacore Inc.) by amine coupling. The lyophilized b-Grb2 was reconstituted in fifty percent DMSO in H20 to make a stock solution of 1mg/rnL and stored at -80 C. A 1: 12.5 dilution of b-Grb2 was used for immobilization, by dilution in acetate buffer pH-5.0, with 5% DMSO. IXPBS
(phosphate buffered saline, pH 7.4) was used as the running buffer.
[00103] An immobilization wizard was used to optimize the immobilization target. For b-Grb2, 2500-5000 resonance units (RU) of protein were captured on the CM5 sensor chip.
Small molecules were serially diluted in running buffer to the concentrations (1.25 nM -1500 nM). as indicated in each sensorgram and injected at 25 C at a flow rate. of 30 L/min for 2 minutes. Varying concentrations of small molecules were injected in increasing concentrlqtions, and every injection was performed in duplicate within each experiment. In order to subtract background noise from each data set, all samples were also 'run over an unmodified reference surface and random injections of running buffer were performed throughout every experiment ("double referencing"). Data were fit to a simple 1: 1 interaction model, using the global data analysis program CLAMP; Myszka et al., Trends Bioclaena. Sci. 1995, 23, 149-150.
[00104] , Effect of Macrocyclization on Grb2 SH2 Domain Bindin'g Affinity.
Using plasmon resonance techniques, steady state KD values were obtained for direct binding of peptides 2, 3 and 4 to chip-bound Grb2 SH2 domain protein. Relative to the open-chain compound 2 (5610 ~: 75.0 nM), macrocycles 3 (KD = 22.7 0.455 nM) and 4 (54.9 0.945 nM) provided two orders of magnitude potency enhancements.
[00105] Grb2 SH2 Domain-Binding Affinity. Binding affinity of 24 to Grb2 SH2 domain protein was determined. Complex binding kinetics were observed with Kd values of 9.3 10.1 nM and 21.3 0.5 M, respectively.
[00106] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
[00107] - The use of the terms "a" and "an" and "the" and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms "comprising," "having,"
"including," and "containing" are to be construed as open-ended terms (i.e., meaning "including, but not limited to,") unless otherwise noted.' Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein.
All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed..' No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
[00108] Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropri4te, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any corimbination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or othervvise- clearly contradicted by context.
[0033] In the embodiments of the invention, R3 can be hydrogen (unsubstituted), azido, amino, oxalylamino, carboxy C1-C6 alkyl, C1-C6 alkoxycarbonyl C1-C6 alkyl,.
aminocarbonyl C1-C6 alkyl, and C1=C6 alkylcarbonylamino; wherein the alkyl portion of R3 may be optionally substituted with a substituent, e.g., selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C1-C6 alkyl, CI-C6 alkyl, Cl-C6 alkoxy, and keto, and any combination thereof.
[0034] In the embodiments of the invention, R4 and R5, independently, can be hydrogen, C1-C6 alkyl, cycloalkyl, heterocyclyl, or together form cycloalkyl or beterocyclyl, wherein the cycloalkyl can be a C3-C7 cycloalkyl, and the heterocyclyl can be a 3-7 membered ring with at least one of N, 0, and S.
[0035] In the embodiments of the invention, R6 can be a C2-C6 alkenylenyl or alkynylenyl group, specifically alkenylenyl, any of which may be optionally siubstituted, e.g., with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof.
[0036] In a specific embodiment, Rl-Rb are together as described in paragraphs [0027]-[0031].
[0037] In the embodiments of the invention, RI can be C6-C14 aryl C1-C6 alkylamino carbonyl, for example, Clo aryl C1-C6 alkylamino carbonyl, such as naphthyl methylamino carbonyl, e.g., 1-naphthyl methylamino.
[0038] In the embodiments of the invention, a specific example of R2 can be phosphono C1-C6 alkyl, optionally substituted with a substituerit, e.g., selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, alkyl, alkoxy, and keto, and any combination thereof; particularly, R2 can be phosphonomethyl.
[0039] In the embodiments of the invention, R3 can be carboxy C1-C6 alkyl, e.g., carboxymethyl.
[0040] In the embodiments of the invention, R6 can be allyl.
[0041:] The present invention also provides corapounds of the formula II:
R'1 CHz)m-N NHz R~
R6=
NH p s (II), wherein Rl and Rl' are the same and are C1-C6 alkyl or Rl and Rl' together form a C4-C$
cycloalkyl; R2, in combination with the phenyl ring, is a phenylphosphate mimic group or a protected phenylphosphate mimic group; R3 is hydrogen, azido, amino, oxalylamino, carboxy C1-C6 alkyl, C1-C6 alkoxycarbonyl C1-C6 alkyl, aminocarbonyl CI-C6 alkyl, or C1-C6 alkyl carbonylamino; wherein the alkyl portion of R3 may be optionally substituted with a substrtuent selected from the group consisting of halo, hydroxy, c.arboxyl,arnino, amino C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination tliereof; R4 and R5, independently, are hydrogen, C1-C6 alkyl, C4-C8 cycloalkyl, or heterocyclyl, or R4 and R5 together form a C4-C8 cycloalkyl or heterocyclyl;
R6 is a group having 1-6 carbon atoms, which may be optionally have a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C1-C6 alkyl, C1-C6 alkoxy., and keto, and any combination thereof; and m is 1 or 2;
or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof; and specifically, compounds wherein m is 1.
[0042] In an embodiment of the compounds of formula II, Rl and Rl' together form a C4-C8 cycloalkyl, e.g., cyclohexyl.
[0043] In any of the embodiments of the compounds of formula 11, R2 is hydroxyl, carboxyl, formyl, carboxy C1-C6 alkyl, carboxy C1-C6 alkoxy, dicarbqxy C1-C6 alkyl, dicarboxy C1-C6 alkyloxy, dicarboxyhalo C1-C6 alkyl, dicarboxyhalo C1-C6-alkyloxy, phosphono, phosphono C1-C6 alkyl, phosphonohalo C1-C6 alkyl, phosphoryl, phosphoryl Ct-C6 alkyl, and phosphoryl Cl-C6 alkoxy, carboxy C1-C6 alkylamino, oxalylamino, RSO2NH- wherein R can be C1-C6 alkyl, halo C1-C6 alkyl,'C6-C14 aryl, C6-C14 aryl CI-C6 alkyl, or trifluoro C1-C6 alkyl, C6-C14 aryl C1-C6 alkyl, phosphino CI-C6 alkyl, CI-C6 alkyl phosphino C1-C6 alkyl, C6-C14 aryl, and C6-C14 aryl C1-C6 alkyl, wherein the alkyl and alkoxy portions of R2 may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto; and any combination thereof; specifically, R2 is hydroxyl, carboxyl, formyl, carboxy C1-C6 alkyl, carboxy C1-C6 alkoxy, dicarboxy C1-C6 alkyl, dicarboxy C1-alkyloxy, dicarboxyhalo C1-C6 alkyl, dicarboxyhalo C1-C6 alkyloxy, phosphono, phosphono C1-C6 alkyl, phosphonohalo CI-C6 alkyl, phosphoryl, phosphoryl C1-C6 alkyl, or phosphoryl CI -C6 alkoxy, wherein the alkyl and alkoxy portions may be optionally substituted with a substituent selected from the group. consisting of halo, hydroxy, carboxyl;
amino, amino C1-C6 alkyl, CI-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof.
Iri a particular embodiment, R2 is hydroxyl, carboxyl, formyl, carboxy C1-C6 alkyl, carboxy CI-C6 alkoxy, dicarboxy C1-C6 alkyl, dicarboxy C1-C6 alkyloxy, dicarboxyhalo C1-C6 alkyl, dicarboxyhalo C1-C6 alkyloxy, phosphono, phosphono C1-C6 alkyl, phosphonohalo C1-C6 alkyl, phosphoryl, phosphoryl CI-C6 alkyl, or phosphoryl Ci-C6 alkoxy. A particular example of R2 is phosphonomethyl.
[0044] In any of the embodiments of the compounds of formula II, R4 and R5 together form a C4-C$ cycloalkyl, particularly cyclohexyl.
[0045] In any of the embodiments of the compounds of formula II, R6 is a CZ-C6 alkenylenyl or C2-C6 alkynylenyl group, which may optionally have a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof.
[0046] In any of the embodiments of the compounds of formula II, R3 is carboxy alkyl, e.g., carboxy methyl.
[0047] A specific example of the compound of formula IIa is:
O
ol CH2-NNHZ
O
HN
O NH O
r-OH
HO P S HO
(IIa) or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
[0048] The term "aryl" as used herein refers to an aromatic moiety such as phenyl, naphthyl, anthracenyl, and biphenyl. The term "heterocyclyl" refers to a 3-7 membered ring comprising one or more heteroatoms such as 0, N, and S, and optionally carbon and/or hydrogen. Examples of heterocyclyl groups include pyridyl, piperidinyl, piperazinyl, pyrazinyl, pyrolyl, pyronyl, pyronyl, tetrahydropyranyl, tetrahydrothiopyranyl, pyrrolidinyl, furanyl, tetrahydrofuranyl, thiophenyl, tetrahydrothiophenyl, purinyl, pyrimidinyl, thiazolyl, thiazolidinyl, thiazolinyl, oxazolyl, tetrazolyl, tetrazinyl, morpholinyl, thiophorpholinyl, quinolinyl, and isoquinolinyl. The aryl and heterocyclyl moieties may be fused, as in aryl heterocyclyl, such as, e.g., indole, isoindole, benzimidazole, quinoline, isoquinolinyl, benzoxazolyl, benzofuranyl, isobenzofuranyl, carbazolyl, benzodioxolyl, and the like. The alkyl; alkoxy, or alkylamino groups can be linear or branched. When an aryl group is substituted with a substituent, e.g., halo, amino, alkyl, hydroxy, or alkoxy, the aromatic ring hydrogen is replaced with the substituent and this can take place in any of the available atoms (e.g., carbon atoms) bearing a hydrogen, e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10-position, taking, for the purpose of illustration, the 1-position as the point of attachment of the aryl group. The term "halo" refers to fluorine, chlorine, bromine, or iodine.
[0049] The present invention further provides a composition comprising a pharmaceutically acceptable carrier and an effective (e.g., therapeutically or prophylactically effective) amount of at least one of the compounds described above. The present invention further provides a method of inhibiting an SH2 domain from binding with a phosphoprotein comprising contacting a sample or substance containing an SH2 domain with a compound of the present invention.
[0050] The present invention discloses the use of above compounds in the manufacture of a medicament for the treatment of a condition that responds to the inhibition of phosphoprotein binding to an SH2 domain of a mammal. The present iinvention further provides the use of the above compounds in medicine. The compounds can find use as an SH2 domain binding inhibitor. Examples of SH2 domain-containing proteins are Grb2, Shp2, and STAT3 proteins.
[0051] The pharmaceutically acceptable (e.g., pharmacologically acceptable) carriers described.herein,. for example, vehicles, adjuvants, excipients, or diluents, arewell known to those who are skilled in the art and'are readily available to the public. It is preferred that the pharmaceutically acceptable carrier be one which is chemically inert to the active compounds and one which has no detrimental side effects or toxicity under the conditions of use.
[0052] , The choice of carrier will be determined in part by the particular active agent, as well as by the particular method used to administer the composition.
Accordingly, there are a wide variety of suitable formulations of the pharmaceutical compositiori of the present invention. The following formulations for oral, aerosol, parenteral, subcutaneous, intravenous, intraarterial, intramuscular, interperitoneal, intrathecal, rectal, and vaginal administration are merely exemplary and are in no way limiting.
[0053] Formulations suitable for oral administration can comprise (a) liquid solutions, such as an effective amount of the compound dissolved in diluents, such as water, saline, or orange juice; (b) capsules, sachets, tablets, lozenges, and troches, each containing a predetermined amount of the active ingredient, as solids or granules; (c) powders; (d) suspensions in an appropriate liquid; and (e) suitable emulsions. Liquid formulations can include diluents, such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent, or emulsifying agent. Capsule forms can be of the ordinary hard-or soft-shelled gelatin type containing, for example, surfactants;
lubricants, and inert fillers, such as lactose, sucrose, calcium phosphate, and cornstarch. Tablet forms can include one or more of lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, acacia, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, disintegrating agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible carriers. Lozenge forms can compri~e the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredierit in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the active ingredient, such carriers as are known in the art.
[0054] The compounds of the present invention, alone or in combination with other suitable components can be made into aerosol formulations to be administered via inhalation. These aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.
They also can be formulated as pharmaceuticals for non-pressured preparations, such as in a nebulizer or an atomizer.
[0055] Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The compound can be administered in a physiologically acceptable diluent in a pharmaceutical carrier, such as a sterile liquid or mixture of liquids, including water, saline, aqueous dextrose and related sugar solutions, an alcohol, such as ethanol, isopropanol, or hexadecyl alcohol, glycols, such as propylene glycol or polyethylene glycol, glycerol ketals, such as 2,2-dimethyl-1,3-dioxolane-4-methanol, ethers, such as poly(ethyleneglycol) 400, an oil, a fatty acid, a fatty acid ester or glyceride, or an acetylated fatty acid glyceride with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or a detergent, suspending agent, such as pectin, carbomers, methylcellulose, hydroxypropylmethylcellulose, or.
carboxymethylcellulose, or emulsifying agents and other pharmaceutical adjuvants.
[0056] Oils, which can be used in parenteral formulations include petroleum, animal, vegetable, or synthetic oils. Specific examples of oils include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum; and mineral. Suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters. Suitable soaps for use in parenteral formulations include fatty alkali metal, ammonium, and triethanolamine salts, and suitable detergents include (a) cationic detergents such as, for example, dimethyl dialkyl ammonium halides, and alkyl pyridinium halides, (b) anionic detergents such as, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates, (c) nonionic detergents such as, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylene polypropylene copolymers, (d) amphoteric detergents such as, for example, alkyl-(3-aminopropionates, and 2-alkyl-imidazoline quaternary ammonium salts, and (e) mixtures thereof.
[0057] The parenteral formulations will typically contain from about 0.5 to about 25%
by weight of the active ingredient in.solution. Suitable preservatives and buffers can be used in such formulations. In order to minimize or eliminate irritation at the site of injection, such compositions may contain one or more nonionic surfactants. The quantity of surfactant in such formulations typically ranges from about 5 to about 15%
byweight.
Suitable surfactants include polyethylene sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol. The parenteral formulations can be presented in unit-dose or multi=dose sealed cointainers, such as ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
[0058] The compounds of the present invention may be made into injectable formiilations. The requirements for effective pharmaceutical carriers for injectable compositions are well known to those of ordinary skill in the art; see, e.g., Pharmaceutics and Phaf-inacy Practice, J.B. Lippincott Co., Philadelphia, PA, Banker and Chalmers, eds., pages 238-250 (1982), and ASHP Handbook on Ir jectable Drugs, Toissel, 4i' ed., pages 622-630 (1986).
[0059] Additionally, the compounds of the present invention may be made into suppositories by mixing with a variety of bases, such as emulsifying bases or water-soluble bases. Forrnulations suitable for vaginal administration may be presented as pessaries, tampons; creams, gels, pastes, foams, or spray formulas containing, in addition to the active ingredient, such carriers as are known in the art to be appropriate. Suitable doses and dosage regimens can be determined by conventional range-finding techniques known to those of ordinary skill in the art. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired. In proper doses and with suitable administration of certain compounds, the present invention provides for a wide range of responses. Typically the dosages range from about 0.001 to about 1000 mg/kg body weight of the animal being treated/day.
Preferred dosages range from about 0.01 to about 10 mg/kg body weightlday, and further preferred dosages range from about 0.01 to about 1 mg/kg body weight/day.
[0060] Embodiments of the compounds have the advantage that they are stable to or in presence of enzymes encountered during in vivo use. Embodiments of the compounds can find use in in vitro and in vivo applications. For example, the compounds can find use as molecular probes as well as in assays to identify, isolate, and/or quantitate receptor or binding sites in a cell or tissue. The compounds also can find use in vivo for studying the efficacy in the treatment of various diseases or conditions involving SH2 domains.
[0061] The present invention further provides a method of preventing or treating a disease, state, or condition in a mammal by the use of the compounds of the present invention. In an embodiment, the method involves preventing a disease, state, or condition.
In another embodiment, the method involves treating an existing disease, state, or condition.
[0062] In an embodiment, the method involves inhibition of SH2 domain binding with a phosphoprotein. The SH2 domain may involve one or more of the following proteins:
Shp2; STAT3, Src, Lck, Eps, ras GTPase-activating protein (GAP), phospholipase C, PI-3 kinase, Fyn, Lyk, Fgr, Fes, ZAP-70, Sem-5, p85, SHPTP1, SHPTP2, corkscrew, Syk, Lyn, Yes, Hck, Dsrc, Tec, Atk/Bpk, Itk/Tsk,Arg, Csk, tensin, Vav, Emt, Grb2, BCR-Abl, Shc, Nek, Crk, CrkL, Syp, Blk, 113TF, 91TF, and Tyk2, especially Grb2, Shp2, and STAT3.
[0063] Grb2 is an adaptor protein with N- and C-terminal src homology 3 (SH3) domains and a central src homology 2 (SH2) domain. The SH2 domain can bind to phosphoTyr residues of receptors or other adaptor proteins, such as SHC. The domains bind the Ras exchange factor SOS, but can also bind to other adaptor proteins such as GAB 1' and GAB2. Thus, Grb2 is involved in activation of Ras but can also play a role in other signaling pathways in mammalian cells.
[0064] Shp2 is a tyrosine phosphatase that is recruited into tyrosine kinase signaling pathways through binding of its two amino-terminal SH2 domains to specific phosphotyrosine motifs. Shp2 is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules -that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and onc genic transformation. Shp2 contains two tandem Src homology-2 domains, which, function as phosphotyrosine binding domains and mediate the interaction with its substrates. Shp2 is widely expressed in most tissues arid plays a regulatory role in various cell-signaling events that are important for a diversity of cell functions, such as mitogenic activation, metabolic control, transcription regulation, and cell migration, [0065] Signal Transducers and Activators of Transcription (STATs) are transcription factors that are phosphorylated by JAK kinases in response to cytokine activation of a cell surface receptor tyrosine kinases. Upon activation, the STATs dimerize and are localized to the nucleus where they activate transcription of cytokine-responsive genes.
There are at least three JAK kinases and at least six STAT proteins involved in this complex signaling pathway. Cytokines that activate STAT3 include growth hormone, IL-6 family cytokines, and G-CSF. STAT3 induces progression through the cell cycle, prevents apoptosis and upregulates oncogenes, such as c-myc and bcl-X and may play a role in oncogenesis.
STAT3 has been shown to play a critical role in hematopoiesis. The importance of STAT3 is underscored by the failure of mice lacking STAT3 to survive embryogenesis.
Crosstalk from pathways other than JAK kinases also leads to phosphorylation and activation of STAT3 as indicated by a role of mTOR (mammalian target of rapamycin, or p70 S6 kinase) and IVIAP'kinase'pathways in STAT3 activation and signaling.
[0066] The method of treatment or prevention of a diseases comprises administering to the mammal one or more compounds of the present invention. The disease, state, condition can be a cancer, e.g., a breast cancer or an ovarian cancer, or a tumor such as a solid tumor, e.g., a brain tumor, a prostate tumor, and the like, leukemia including chronic myelocytic leukemia, lymphoma, an autoimmune disease, an inflammatory disease, a metabolic disease, diabetes, obesity, or cardiovascular disease.
[0067] The present invention farther provides a method of enhancing the therapeutic effect of a treatment rendered to a mammal comprising administering a compound in conjunction with the treatment. By conjunction, it is meant that the inhibitor can be used in any suitable manner, for example, prior to, simultaneous with, or post-administration of the therapeutic agent. Synergistic effects are observed when the SH2 domain binding inhibitor is used in combination with other treatments known to those skilled in the art. The inhibitor enhances the cytotoxicity of the cheinotherapeutic treatments. Cancer treatment is particularly suitable for this combination treatment.
[0068] ' The cancer may involve any number of mechanisms. A majority of human breast cancers are dependent upon activation of the Ras signaling pathways through activation of growth factor receptot as the means to achieve continuous cellular proliferation. For example, the cancer may involve overexpression of Her-2/neu. The cancer can be mediated through BCIZ-Abl or the expression of erbB-2 receptor.
In cells transformed by p185 erbB-2 overexpression, therapeutic agents affectirig Grb2 function at its SH2 domain may interrupt the flow of signal transduction to the Ras pathway and thus result in reversal of the cancer phenotype.
[0069] The therapeutic treatment can include chemotherapy, radiation therapy, and/or a biological therapy. Examples of chemotherapy include the use of cancer treatment agents such as alkylating agents, hormonal agents, antimetabolites, natural p'roducts,.and miscellaneous agents. Particular examples of cancer treatment agents include paclitaxel, 5-fluoruracil, and doxorubicin. Examples of biological therapy include the use of a protein such as an antibody (monoclonal or polyclonal) or a recombinant protein. An example of an antibody is herceptin, which is targeted for inhibiting the erbB-2 receptor. In embodiments, the enhancement of the therapeutic effect comprises blocking of a cell survival factor in the mammal and/or triggering, e.g., enhancing or speeding up, of cell apoptosis. The treatment can be carried out in vivo, and/or in vitro.
[0070] , The Grb2 SH2 binding inhibitors are effective in inhibiting the association or binding of Grb2 with activated receptor PTKs. Interaction of native Grb2 protein with phosphotyrosinylated proteins including receptor PTKs can be monitored by immunoprecipitating Grb2 and detecting the amount of phosphotyrosinylated proteins which are coprecipitated using anti-phosphotyrosine Western Blotting.
[0071] The compounds of the present invention can be prepared by any,suitable method, for example, a method that advantageously utilizes C-terminal allylglycine amides, for example, compound 1 in Figure 1 in a method involving ring closing metathesis (RCM) reaction of allylglycines onto a(3-vinyl-containing residue;. see, e.g., Figures 1 -3. For examples of RCM reactions, see, Gao et al., Org. Lett. 2001, 3, 1617-1620;
Reichwein et al., Angew. Clzem., Int. Ed. 1999, 38, 3684-3687, J. Org. Chem., 2000, 65, 6187-6195; and J. Org. Chem., 2000, 65, 2335-2344; Stymiest et al., Org. Lett., 2003; 5, 47-49; Miller et al., J. Am. Chem. Soc., 1995, 117, 5855-5856; and Dekker et al., Org. Biomol.
Chem., 2003, 1, 3297-3303. The RCM reaction advantageously allows ring closure with retention of desired functional groups, e.g., phenylphosphate functionality or the chemical (e.g., a lipophile comprising a carbonyl group) functionality at or near the site of ring juncture(s). L- and D-allylglycines and many of the required terminal amines may be commercially available, thereby making the synthesis more readily accessible than certain other methods, for example, those involving the use of C-terminal2-allyl-3-aryl-l-propanamides that lacked the a-carboxyl portion of allylglycine residues. In addition to solution chemistries, the preparation of multiple analogues may be made possible through the use of solid-phase chemistries.
[0072] The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope.
[0073] This example demonstrates a method of preparing compounds in accordance with an embodiment of the invention.
[0074] Reactions were carried out under argon. Anhydrous solvents were purchased from Aldrich Chemical Corporation and used without further drying. Combustion analyses were obtained from Atlantic Microlab, Inc., Norcross, GA. 1H NMR spectra were obtained using a Varian 400 MHz spectrometer and are reported in ppm relative to TMS
and referenced to the solvent in which they were run. Fast atom bombardment mass spectra (FABMS) were acquired with a VG analytical 7070E mass spectrometer. HPLC
separations were conducted using a. Waters Prep LC4000 system with photodiode array detection and either a J-sphere ODS-H80 column (20 x 250 mm) with a solvent system consisting of 0.1 % aqueous TFA (v/v, solvent A) / 0.1 % TFA in MeCN (v/v, solvent B).
[0075] N-Boc-L-A11y1Gly-(1-naphthyl)methyl amide (5a). An ice-cold solution of N-Boc L-allylglycine=dicyclohexylamine salt (Fluka).(1.61 g, 4.05 mmol) in 0.1 N
HCl (100 mL) was extracted with ice-cold EtOAc (3 x 50 mL) and the combined extracts were dried (Na2SO4) and taken to dryness to yield the free amine as a syrup (898 mg). To a solution of this syrup in anhydrous DMF (9 mL) was added 1-hydroxybenzotriazole=H2O.(HOBt) (601 mg, 4.46 mmol) and 1,3-diisopropylcarbodiimide (DIPCDI) (696 L, 4.46 mmol) and after minutes, (1-naphthyl) methylamine (653 L, 4.46 mmol) and the resulting mixture was stirred at room temperature overnight. The mixture was taken to dryriess under high vacuum at 50 C and the resulting syrup was dissolved in EtOAc and purified by silica gel flash chromatography (hexanes in EtOAc) to yield product 5a as cream-colored crystals (1.15 g, 80% yield). H NMR (CDC13) S 1.31 (s, 9 H), 2.44 - 2.53 (m, 2 H), 4.08 - 4.16 (m, 1 H), 4.81 - 4.94 (m, 2 H), 5.04 - 5.12 (m, 2 H), 5.64 - 5.78 (m, 1 H), 6.32 -6.38 (br m, 1 H), 7.39 (dd, J= 7.0 and 10.7 Hz, 1 H), 7.46 (dd, J= 1.5 and 6.8 Hz, 1 H), 7.49 (dd, J= 1.3 and 2.1 Hz, 1 H), 7.59 (dd, J= 1.6 and 7.8 Hz, 1 H), 7.77 - 7.80 (br-m, 1H), 7.83 -7.86 (br-m, 1 H), 7.94 (br-d, J= 8.0 Hz, 1 H). FAMBS m/z 355.2 (MH).
[0076] N-Boc-D-Al1ylGly-(1-naphthyl)methyl amide (5b). Treatinent of N-Boc-D-allylglycine=dicyclohexylamine salt (PepTech) (2.72 g. 6.86 mmol) in a manner similar to that used to prepare 5a, provided product 5b as a light yellow solid in quantitative yield. H
NMR: refer to that provided for enantiomeric 5a. FABMS m/z 355.1 (MH+).
[0077] N-Fmoc-L-Asn-L-A11y1Gly-(1-naphthyl)methyl amide (6a). A solution of 5a (254 mg, .1.00 mmol) in TFA: H20 (9:1) (10 mL) was stirred at room'temperature (1 h), then TFA was removed by rotary evaporation under reduced pressure and the residue was partitioned between saturated NaHCO3 in brine (25 mL) and EtOAc (2 x 25 mL).
The organic extract was dried (Na2SO4); evaporated to an oil (203 mg), taken up in DMF (1 mL) and to this was added an HOBt active ester solution prepared by reacting N-Fmoc-L-asparagine (Novabiochem) (357 mg, 1.10 mmol), HOBt (148 mg, 1.10 mmol) and DIPCIDI
(172 L, 1.10 mmol) in DMF (3 mL), 15 minutes. The resulting clear solution was stirred at room temperature to rapidly yield a thick white suspension. The suspension was diluted with DMF (4 mL) and stirring was continued at room temperature (overnight).
Solvent was removed at 50 C under high vacuum aind the residue was triturated well with MeOH (10 mL), collected by filtration and washed well with MeOH to yield product 6a as a snow-white solid (424 mg, 72% yield). H NMR (DMSO-d6) S 2.24 - 2.56 (m, 4 H), 4.14 -4.20 (m, 3 H), 4.24 - 3.36 (m, 2 HO, 4.66 (d, J= 6.9 Hz, 2 H), 4.89 (br-d, J= 10.4 Hz, 1 H), 4.98 (br-d, J= 17.2 Hz, 1 H), 5.61 - 5.72,(m, 1 H), 6.90 .(br-s, 1 H), 7.24 - 7.40 (m; 8 H), 7.44 -7.50 (m, 2 H), 7.57 (d, J= 8.0 Hz, 1 H), 7.64 (d, J= 5.8 Hz, 2 H), 7.78 = 7.79 (m, 1 H), 7.84 (d, J= 7.5 Hz, 2 H), 7.87 -7.90 (m, 1 H), 8.00 (br-t, J, J= 6.1 Hz, 2 H), 8.46 (br-t, J= 5.6 Hz, 1 H). FABMS m/z 591.3 (MH)+.
[0078] N-Fmoc-L-Asn-D-AllylGly-(1-naphthyl)methyl amide (6b). Treatment of 5b (1.64 g, 6.45 mmol) in a manner similar to that used to prepare 6a from 5a, provided product 6b as white foam in quantitative yield. H NMR (DMSO-d6) 6 2.24 - 2.43 (m, 4 H), 4.06 - 4.14 (m, 3H), 4.25 - 4.34 (m; 2 H), 4.65 (d, J= 5.8 Hz, 2 H), 4.90 (br-d, J= 9.6 Hz, 1 H), 4.98 (br-d, J= 17.5 Hz, 1 H), 5.58 - 5.70 (m, 1 H), 6.89 (br-s, 1 H), 7.24 (dd, J= 7.4 and 15.0Hz,2H),7.30-7.38(m,5H);7.44-7.48(m,2H),7.56(br-d,J=7.6Hz, 1 H), 7.60 (br-t, J= 6.5 Hz, 2 H), 7.75 (br-d, J= 8.0 Hz, 1 H), 7.82 - 7.88 (m, 3 H), 7.96 - 7.99 (m, 1 H), 8.05 (d, J= 8.4 8.4 Hz, 1 H). FABMS fn/z 591.3 (MH)+.
[0079] H-L-Asn-L-A1lylGly-(1-naphthyl)methyl amide (7a). To a suspension of 6a (1.11 g, 1.88 mmol) in DMF (10 mL) was added piperidine (15 equivalents) and the mixture was stirred at room temperature (2 h). Solvent and piperidine were removed under high vacuum to yield a white solid, which was dissolved in MeOH: EtOAc and purified by silica gel flash chromatography (MeOH: EtOAc) to yield free amine 6a as a gel that became a white solid on prolonged exposure to vacuum (540 mg, 78% yield). H NMR (DMSO-d6) S
2.12 - 2.46 (m, 4 H), 3.44 (dd, J= 5.7 and 8.6 Hz, 1 H), 4.30 (br-s, 1 H), 4.63 - 4.53 (m, 2 H), 4:95 (dd, J==2.1 and 10.1 Hz, 1.H), 5.01 (dd, J- 2.1 and 17.2 Hz, 1 H)x 5..61 - 5.72 (m, 1 H), 6.82 (br-s, 1 H), 7.34 - 7.44 (m., 3 H), 7.46 - 7.52 (m, 3 H), 7.79 (br-d, J= 7.6 H, 1 H), 7.87 - 7.92 (m, 1 H), 7.98 - 8.02 (m, 1 H), 8.11 (br-s, 1 H), 8.52 (t, J= 5.9 Hz, 1 H).
FABMS nz/z 369.2 (MH)+.
[0080] N-Fmoc-Ac6c-L-Asn-L-AllylGly-(1-naphthyl)methyl amide (8a). To a solution of amine 7a (368 mg, 1.00 mmol) in DMF (3 mL) was added an HOBt active ester solution prepared by reacting N-Fmoc- 1 -aminocyclohexane carboxylic acid (N-Fmoc-Ac6c-OH) (Advanced ChemTech) (420 mg, 1.10 mmol),'HOBt (148 mg; 1.10 mrmol) and DIPCIDI (172 L, 1.10 mmol) in DMF (3 mL), 10 minutes and the resulting solution was stirred at room temperature (overnight). The reaction mixture was taken to dryness under high vacuum and purified by silica gel flash chromatography (MeOH: EtOAc) to yield product 8a as white foam in quantitative yield. H NMR (CDC13) 8 1.10 - 1.82 (m, 10 H), 2.38 - 2.56 (m, 2 H), 2.73 - 2.79 (m, 2 H), 4.02 - 4.23 (m, 3 H), 4.35 - 4.45 (m, 2 H), 4.62 (dd, J= 4.7 and 14.8 Hz, 1 H), 4.87 (dd, J= 1.7 and 10.3 Hz, 1 H), 4.94 - 5.01 (m, 2 H), 5.58 - 5.75 (m, 1 H), 6.82 (s, 1 H), 7.18 - 7.39 (m, 9 H), 7.40 -7.42 (m, 1 H), 7.46 - 7.48 (m, 1 H), 7.61 - 7.64 (m, 2 H), 7.68 - 7.74 (m, 3 H), 7.92 (d, J= 8.6 Hz, 1 H), 7.96 (s, 1 H), 8.27 (d, J= 5.7 Hz, 1 H). FABMS m/z 716.2 (MH)+.
[0081] N-Boc-Ac6c-L-Asn-D-A11y1Gly-(1-naphthyl)methyl amide (8b). Protected peptide 6b (300 mg, 0.507 mmol) was treated with 20% Et2NH in DMF (5 mL) for minutes at room temperature. Concentration under reduced pressure gave the corresponding crude amine. To a stirred solution of the amine in dry DMF (1 mL) and 1-hydroxy-,7-azabenzotriazole (HOAt) in DMF (0.5 M, 1.11 mL, 0.558 mmol) were added N-Boc-Ac6c-OH (135 mg, 0.558 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide=HCl (EDCI=HCI) (116 mg, 0.609 mmol), and the mixture was stirred for 12 h at room temperature. The mixture was extracted with EtOAc, and the extract was washed successively with 5% citric acid solution, brine, 5% aqueous NaHCO3 and brine, and dried -over Na2SO4. Concentration followed by, flash chromatography over silica gel using CH2C12-MeOH (95:5) provided product 8b as colorless solid (84 mg, 28%
yield). 1H-NMR (400 MHz, CDC13) 6 1.25 (m, 2 H), 1.40 (s, 9 H), 1.63 (m, 6 H), 1.84 (m, 1 H), 2.03 (m, 1 H), 2.39 (dd, J= 16.5 and 4.2 Hz, 1 H), 2.54 (ddd, J= 14.6, 10.7 and 7.7 Hz, 1 H), 2.88 (m, 1 H), 2.94 (dd, J= 16.5 and 4.9 Hz, 1 H), 4.32 (br, 1 H), 4.45 (m, 1 H), 4.58 (m, 2 H), 4.90 (s, 1 H), 5.05 (m, 2 H), 5.15 (dd, J= 16.9 and 1.6 Hz, 1 H), 5.35 (br, 1 H), 5.79 (m, 1 H), 7.16 (m, 1 H), 7.41 (m, 2 H), 7.49 (m, 2 H), 7.68 (d, J= 8.8 Hz; 1 H), 7.74 (m, 2 H), 7.81 (d, J= 7.9 Hz, 1 H), 8.00 (d, J= 8.6 Hz, 1 H). FABMS nz/z 594 (MH) [0082] = H-Ac6c-L-Asn-L-A11y1Gly-(1-naphthyl)methyl amide (9a). To a solution of 8a (738 mg, 1.00 mmol) in DMF (5 mL) was added piperidine (1.0 mL, 10 mmol) and the solution was stirred at room temperature (40 minutes). Solvent was then removed under high vacuum at 50 C and the resulting residue was purified by silica gel flash chromatography (MeOH: EtOAc) to provide an oil. Lyophilization from dioxane provided product 9a as a white solid (343 mg; 84% yield). FABMS m/z 494.3. (MH+). ' [0083] H-Ac6c-L-Asn-D-A11y1Gly-(1-naphthyl)methyl amide (9b). Preparation of peptide 9b by solid-phase methods is outlined below.
[0084] [(2R,3R)-3-(4-Di-tert-butyloxyphosphonomethyl)phenyl-2-(tert=
butyloxycarbonylmethyl)pent-4-enyl]-Ac6c-L-Asn-L-A11y1Gly-(1-naphthyl)methyl amide (lla). To a stirred solution of 9a (70 mg, 0.141 mmol) in dry DMF (0.30 mL) and HOAt in DMF (0.5 M, 0.311 mL, 0.155 mmol) were added protected'pTyr mimetic 10 (77 mg, 0.155 mmol; Wei et al., J. Med. Claem. 2003, 46, 244-254) and EDCI-HCI (32 mg, 0.170 mmol), and the mixture was stirred for 12 h at 50 C. The mixture was extracted with EtOAc, and the extract was washed successively with saturated citric acid solution, brine, 5% aqueous NaHCO3 solution and brine, and dried over Na2SO4.
Concentration followed by flash chromatography over silica gel using CHZC12: MeOH (95:5) provided lla as colorless solid (16 mg, 12% yield). 1H-NMR (400 MHz, CDC13) 8'0.72 - 1.62 (m, 37 H), 2.47 (m, 2 H), 2.62 (m, 3 H), 2.82 (m, 1 H), 2.96 (d, J= 21.5 Hz, 2-H), 3.02 (m, 1 H), 3.51 (m, 1 H); 4.31 (m, 1 H), 4.44 (m, 1 H), 4.83 (dd, J= 15.0 and 5.3 Hz, 1 H), 4.97 (dd, J=
15.0 and 6.0 Hz, 1 H), 5.05 (m, 3 H), 5.15 (dd, J= 17.1 and 1.6 Hz, 1 H), 5.25 (br, 1 H), 5.69 (m, 1 H), 5.81 (m, 1 H), 6.22 (s, 1 H), 6.71 (br, 1 H), 7.11 - 7.25 (m, 5 H), 7.35 - 7.55 (m, 5 H), 7.59 (d, J= 8.3 Hz, 1 H), 7.72 (d, J= 8.1 Hz, 1 H), 7.81 (d, J= 9.2 Hz, 1 H), 8.04 (d, J= 8.1 Hz, 1 H). FABMS m/z 972 (MH)+.
[0085] [(2R,3R)-3-(4-Di-tert-butyloxyphosphonomethyl)phenyl-2-(tert-butyloxycarbonylmethyl)pent-4-enyl]-Ac6c-L-Asn-D-A11y1Gly-(1-naphthyl)methyl amine (llb). Protected peptide 8b (70.mg, 0.117 mmol) was treated with TFA:
anisole (10:1, 5.5 mL) for 2 h at room temperature. Concentration under reduced pressure gave the corresponding amine 9b as its TFA salt. To a stirred solution of the amine 9b in dry DMF
(0.300 mL) and HOAt in DMF (0.5 M, 0.259 mL, 0.129 mmol) were added protected pTyr mimetic 10 (64 mg, 0.129 mmol), EDCI=HC1(27 mg, 0.141 mmol) and i-Pr2NEt (0.040 mL, 0.234 mmol) at 0 C, and stirring was continued for 24 h at 50 C., The mixture was extracted with EtOAc, and the extract was washed successively with saturated citric acid solution, brine, saturated aqueous NaHCO3 solution and brine, and dried over Na2SO4.
Concentration followed by flash chromatography over silica gel using CHZC12:
MeOH
(95:5) provided llb as colorless solid (52 mg, 45% yield). 1H-NMR (400 MHz, CDC13) 6 0.78 - 1.66 (m, 37 H), 2.51 - 2.73 (m, 4 H), 2.80 (m, 1 H), 2.88 - 3.05, (m, 4 H), 3.32 (t, J=
10.0 Hz, 1 H), 4.11 (m, 1 H), 4.52 (m, 1 H), 4.77 (dd, J= 15.5 and 5.1 Hz, 1 H), 4.99 - 5.23 (m, 6 H),, 5.70 - 5.99 (m, 4 H), 7.06 (m, 2 H), 7.20 (m, 2 H), 7.37 (m, 1 H), 7.43 - 7.61 (m, 6 H), 7.72 (d, J= 8.1 Hz, 1 H), 7.82 (m, I H), 8.04 (d, J= 8.3 Hz, 1 H). FABMS
nzlz 972 (MH)+.
[0086] Cyclo{[(2R,3R)-3-(4-di-tert-butyloxyphosphonomethyl)phenyl-2-(tert-butyloxycarbonylmethyl)pent-4-enyl]-Ac6c-L-Asn-L-AIlylGly}-(1-naphthyl)methyl amide (12a). To a solution of lla (15 mg, 0.015 mmol) in CHZC12 (3.7 mL) was added 2nd generation Grubbs RCM catalyst, [1;3-bis-(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(phenylmethylene)-(tricyclohexylphosphine)ruthenium]
[((PCy3)(Im(Mes)2)Ru=CHPh)] (Aldrich) (6.5 mg, 0.0077 mmol) in CH2C12 (1.3 mL) under argon. The reaction mixture was stirred at 45 C for 24 h. The crude reaction mixture was evaporated in vacuo and the residue was purified by silica gel chromatography using CH2C12: MeOH (10:1) to provide 12a as colorless powder (11 mg, 73% yield). 'H-NMR
(400 MHz, CDC13) S 1.16 - 1.58 (m, 30 H), 1.61 (m, 1 H), 1.72 (rn, 1 H), 1.89 (m, 4 H), 2.07 (m, 1 H), 2.35 (m, 1 H), 2.46 - 2.73 (m, 4 H), 2.99 (m, 3 H), 3.57 (m, 1 H), 3.88 (m, 1 H), 4.83 (m, 2 H), 4.90 (m, 1 H), 5.13 (m, 2 H), 5.83 (dd, J= 15.3 and 7.6 Hz, 1 H), 6.24 (br, 1 H), 7.08 (m, 1 H), 7.11 - 7.25 (m, 4 H), 7.34 - 7.56 (m, 4 H), 7.68 (m, 1 H), 7.73 (d, J
= 8.3 Hz, 1 H), 7.84 (d, J= 7.8 Hz, 1 H), 7.98 (d, J= 8.8 Hz, 1 H), 8.03 (d, J= 8.3 Hz, 1 H).
FABMS mlz 944 (MH)+. , [0087] Cyc1o{[(2R,3R)-3-(4-di-tert-butyloxyphosphonomethyl)phenyl-2-(tert-butyloxycarbonylmethyl)pent-4-enyl]-Ac6c-L-Asn-D-A11y1Gly}-(1-iiaphthyl)methyl amide (12b). To a solution of llb (55 mg, 0.057 mmol) in CH2C12 (25 mL) was added [((PCy3)(Im(Mes)2)Ru=CHPh)] (27 mg, 0.032 mmol) in CH2C12 (8 mL) under argon and the reaction mixture was stirred at 45 C (48 h). The crude reaction mixture was then evaporated in vacuo, and residue was purified by silica gel flash chromatography to provide 12b as yellow oil (28 mg, 52% yield). 'H NMR (CDC13) S 8.04 (m, 1H), 7.87 (d, 1H, J=
8.5 Hz), 7.83 (m, 1H), 7.75 (d, 1 H, J= 8.3 Hz), 7.54-7.40 (m, 6H), 7.24 (dd, 2H, J= 2.4 Hz & 8.3 Hz), 7.14 (d, 2H, J= 7.9 Hz), 6.81 (d, 1 H, J= 7.5 Hz), 5.98 (s, 1 H), 5.81 (dd, 1 H, J
9.1 Hz & 15.5 Hz), 5.72 (s, 1 H), 5.40 (m, 1 H), 5.02 (m, 1 H), 4.79 (dd, 1H, J=. 5.0 Hz &
14.9 Hz), 4.57 (m, 1H), 4.48 (m, 1H), 3.54 (m, 1H), 3.06 (m, 1H), 3.02 (d, 2H, J= 21.5 Hz), 2.97 (m, 1H), 2.88 (dd, 1H, J= 5.6 Hz & 15.9 Hz), 2.63 (dd, 1H, J= 4.1 Hz &
16.1 Hz), 2.43 (dd, 1H, J= 11.2 Hz & 17.2 Hz), 2.23 (m, 1H), 1.95 (dd, 1H, J- 3.0 Hz &
17.2 Hz), 1.86-1.44 (m, 6H), 1.42 (s, 9H), 1.40 (s, 9H), 1.36 (s, 9H), 1.31-1.20 (m, 4H). FABMS na/z 944 (MH)+.
[0088] Cyclo{[(2R,3R)-3-(4-dihydroxyphosphonomethyl)phenyl-2-(hydroxycarbonylmethyl)pent-4-enyl]-Ac6c-L-Asn-L-AllylGly}-1-naphthyl)methyl amide (3). Protected peptide 12a (10 mg, 0.010 mmol) was treated with TFA: H20 (95:5, 2 mL) for 2 h at room temperature. Concentration followed by preparative HPLC
purification (linear gradient 30 to 40% B in A over 30 minutes).provided 3 as colorless powder (4.6 mg, 56% yield). 'H-NMR (400 MHz, DMSO-d6) b 1.23 (m, 1 H), 1.48 (m, 5 H), 1.78 (m, 4 H), 2.06 (m, 1 H), 2.3 5.(m, 1 H), 2.42 - 2.72 (m, 4 H), 2.92 (d, J= 21.2 Hz, 2 H), 3.21 (m, 1 H), 4.02 (m, 1 H), 4.34 (m, 1 H), 4.58 (in, 1 H), 4.72 (dd, J= 1.5.4 and 5.2 Hz, 1 H), 4.81 (dd, J
= 15.6 and 5.6 Hz, 1 H), 5.34 (m, 1. H), 5.84 (dd, J= 15.2 and 8.0 Hz, 1 H), 6.86 (br, 1 H), 7.06 (d, J= 8.0 Hz, 1 H), 7.18 - 7.29 (m, 4 H), 7.36 (br, 1 H), 7.42 - 7.60 (m, 4 H) 7.70 (d, J= 8.5 Hz, 1 H), 7.83 (d, J= 7.2 Hz, 1 H), 7.94 (d, J= 7.2 Hz, 1 H), 8.06 (d, J= 8.5 Hz, 1 H), 8.16 (s, 1 H), 8.31 (t, J= 5.4 Hz, 1 H). FABMS mlz 774 [(M-H)-].
[0089] - Cyclo{[(2R,3R)-3-(4-dihydroxyphosphonomethyl)phenyl-2-(hydroxycarbonylmethyl)pent-4-enyl]-Ac6c-L-Asn-D-A11y1Gly}-(1-naphthyl)methyl amide (4). A solution of 12b (22 mg, 0.023 mmol) in a mixture of TFA:
triethylsilane (TES): H20 (4.0 mL, v:v, 3.7:0.1:0.2) was stirred at room temperature (1 h).
Solvent was evaporated in vacuo and residue was purified by HPLC using a linear gradient using a linear gradient (5% to 95% B over 15 minutes) provided product 4 as white solid (8.4 mg, 46%
yield). 'H NMR (DMSO-d6) S 8.22 (m, 1H), 8.15 (s, 1H), 8.09 (m, IH), 8.00 (m, 1H), 7.84 (dd, 1 H, J= 2.6 Hz & 6.7 Hz), 7.72 (d, 1 H, J= 6.4 Hz), 7.46-7.3 6 (m, 4H), 7.31 (s, 1 H), 7.12-7.06 (m, 5H), 6.83 (s, 1H), 5.$0 (dd, 1H, J= 9.2 Hz & 15.9 Hz), 5.27 (m, 1H), 4.72-4.64 (m, 2H), 4.56 (m, 1H), 3.91 (m, 1H), 3.81 (m, 1H), 3.16 (m, 1H), 2.69 (d, 2H, J= 20.8 Hz), 2.60-2.50 (m, 3H), 2.25 (m, 1H), 1.84 (m, 1H), 1.78-1.16 (m, 10H). FABMS
fn/z 775 M}, 776 (MH)+.
[0090] . Conversion of 4 to Its Tri-sodium Salt. Compound 4 (5.2 mg, 0.0067 mmol) was dissolved in a solution of acetonitrile: H20 (1.0 mL, v/v = 1:1) and to this solution was added a NaHCO3 solution (0.334 mL, 0.0201 mmol) and the resulting solution was lyophilized to provide the tri-sodium salt of 4 as white solid (5.6 mg, 100%
yield).
[0091] General Procedure for Reductive Amination on Resin. To a suspension of (4-formyl)-3-methoxyphenoxy)butyryl-NovaGel HL resin 13 (55 mg, 0.030 mmol;
Novabiochem, Inc.) in dry 1,2-dichloroethane-trimethyl orthoformate (2:1, 1.2 mL) were added 1-naphthylmethylamine (0.044 mL, 0.30 mmol) and NaBH(OAc)3 (64 mg, 0.30 mmol), and agitation was continued for 12 h at room temperature. The resin was washed successively with DMF, 10% i-Pr2NEt/DMF and DMF to provide 1V-(1-naphthylmethylamino)-modified resin 14.
[0092] General Procedure for the Solid-Phase Synthesis of Protected Peptides on Resin. Protected peptide-resins were manually constructed by Fmoc-based solid-phase peptide synthesis. Trityl was employed for Asn side-chain protection. Fmoc deprotection was achieved by 20% piperidine in DMF (2 x 1 min, 1 x 20 min). Fmoc-amino acids were coupled by treatment with 5 equivalents of Fmoc-amino acid and coupling reagents [HATU/HOAt for Gly and Al1ylGly for 6 h; (DIPCDI)/HOBt for Asn(Trt) for 2 h;
DIPCDI/HOAt for Ac6c for 6 h] in DMF. The pTyr mimetic 10 was coupled using DIPCDI/I4OAt in DMF for 2 days at 50 C.
[0093] [(2R)-3-(4-Dihydroxyphosphonomethyl)phenyl-2-(hydroXycarbonylmethyl) propionyl]-Ac6c-L-Asn-Gly-(1-naphthyl)methyl Amide (2). Protected peptide resin 16 (87 mg, 0.030 nunol) resulting from elaboration of modified resin 14 using the appropriate amino acids as described above under general procedures for solid-phase synthesis, was treated with TFA: H20 (95:5, 10 mL) for 2 h at room temperature. After removal of resin by filtration, the filtrate was concentrated and purified by preparative'(linear gradient from 30 to 40% B in A over 30 min) to provide 2 as colorless powder (10 mg, 45%,yield based on resin substitution). 1H-NMR (400 MHz, DMSO-d6) S 1.00 - 1.29 (m, 2 H), 1.29 - 1.63 (m, 6 H), 1.82 (m, 2 H), 2.04 (dd, J= 16.6 and 3.9 Hz, 1 H), 2.43 - 2.65 (m, 4 H), 2.90 (d, J
= 21.3 Hz, 2 H), 2.96 (m, 1 H), 3.11 (m, 1 H), 3.68 (dd, J= 16.9 and 5.7 Hz, 1 H), 3.83 (dd, J= 16.9 and 6.4 Hz, 1 H), 4.34 (dt, J= 7.4 and 5.7 Hz, 2 H), 4.73 (m, 2 H), 6.91 (br, 1 H), 7.09 - 7.19 (m, 4 H), 7.42 (m, 3 H), 7.54 (m, 2 H), 7.73 (d, J= 7.4 Hz, 1 H);
7.81 (m, 1 H), 7.90 - 8.00 (m, 2 H), 8.06 (m, 1 H), 8.11 (t, J= 5.7 Hz, 1 H), 8.28 (s, 1 H).
FABMS rnlz 736 [(M-H)"].
[0094] H-Ac6c-L-Asn-n-A11y1Gly-(1-naphthyl)methyl amide (9b). Protected peptide resin 15c (429 mg, 0.15 mmol), resulting from elaboration of modified resin 14 using the appropriate amino acids as described above under general procedures for solid-phase synthesis, was treated with TFA: H20 (95:5, 10 mL) for 2 h at room temperature. After filtration, the filtrate was concentrated and neutralized with saturated NaHCO3 solution.
The whole was extracted with EtOAc, and the extract was washed with brine, and dried over Na2SO4. Concentration followed by silica gel flash chromatography using EtOAc:
MeOH (8:2) provided 9b (74 mg, quant.) as colorless solid. 1H-NMR (400 MHz, DMSO-d6) 8 1.13 (m, 1 H), 1.27 (m, 2 H), 1.36 - 1.57 (m, 5 H), 1.66 (m, 2 H), 2.34 (m, 1 H), 2.40 -2.58 (m, 3 H), 4.31 (m, 1 H), 4.45 (m, 1 H), 4.74 (d, J= 5.8 Hz, 2 H)y 4.98 (d, J= 10.2 Hz, 1 H), 5.04 (d, J 17.2 and 1.6 Hz,.1'H), 5.69 (m, 1-H), 6.95 (br, 1 H), 7.45 (m, 3 H), 7.54 (m, 2 H),, 7.84 (dd, J= 7.0 and 2.3 Hz, 1 H), 7.92 (m, 2 H), 8.06 (m, 1 H), 8.48 (m, 2 H).
FABMS m/z 494 (MH+).
[0095] Preparation of 15a, 15b, 17a, 17b, 18a, and 18b. As illustrated iri Figure 3, elaboration of resin 14 by coupling with either N-Fmoc L-allylglycine or N-Fmoc D-allylglycine gave resins 15a and 15b, respectively. Coupling of Asn and Ac6c residues followed by pTyr mimetic 10 yielded resins 17a and 17b, respectively. HPLC
analysis of small samples of cleaved resin provided single major peaks that gave MALDI
mass spectra consistent with the structure of peptides 18a and 18b, respectively. This indicated that the coupling of pTyr mimetic 10 had been achieved satisfactorily. Peptides 18a and 18b may be converted to compounds 3 and 4, respectively, by an RCM reaction.
[0096] Preparation of 20: 1-Chloro-l-cyanocyclohexane (J. Org. Chem. 1968, 33, 2211 '- 2214). To a solution of phosphorus pentachloride (66.8. g, 0.32 mol) and pyridine (34 mL, 0.42 mol) in chloroform (300 mL, HPLC grade), was added cycanocyclohexane 19 (25 mL, 0.21 mol), the mixture was heated to reflux overnight. The reaction mixture was cooled to r.t., poured into crashed ice carefully, and the aqueous phase was extracted by ether (200 mL x 2), the combined organic phase was washed by water (200 mL x 3), sat.
NaHCO3 (100 mL), brine (100 mL), dried over anhydrous Na2SO4, after concentrated, the residue oil was distilled to afford 20 as a colorless liquid 28.6 in 95%
yield. 73 C/4 mmHg;
1H NMR (CDC13) S 2.33 (2 H, m), 2~.00 (2 H, m), 1.83 (2 H, m), 1.751-1.61 (3 H, m), 1.40 (1 H, m); 13C NMR (CDC13) 5 119.5; 57.3, 40.2, 24.0, 23.2.
[0097] Preparation of 21 (Org. Lett. 2004, 6, 501- 503): To a solution of 20 (5.0 g, 34.8 mmol) and allyl bromide (3.25 mL, 38.3 mmol) in dry THF (150 mL) at- 78 C, was added n-BuLi (2.5 M, 15.3 mL, 38.3 mmol); the mixture was stirred at- 78 C for 2 hours before sat. NH4C1(30 mL) was added. The mixture was extracted with ethyl acetate, washed with brine, dried over anhydrous Na2SO4, purified by column (silica gel, hexane and ethyl acetate) to afford 21 as a pale yellow oi13.8 g in 76% yield. 'H NMR
(CDC13) 6 5.90 (1 H, m), 5.20 (2 H, m), 2.30 (2 H, m), 2.00 (2 H, m), 1.85 - 1.50 (6 H, m), 1.25 (2 H, m); 13C NMR (CDC13) S 131.9, 123.0, 119.6, 44.6, 35.3, 25.3, 22.9.
[0098] Preparation of 22. To a solution of C (3.80 g, 25.5 mrriol) in dry ether ( 200 mL) at 0 C, was added LiAlH4 (2.0 g, 52.6 mmol) carefully, the mixture was stirred at r.t.
overnight. The reaction mixture was cooled to 0 C before water (5.0 mL) was added carefully, stirred vigorously until the color turned to white, dried over anhydrous Na2SO4, flitered, and the filtrate was concentrated to a colorless oil (free amine, 3.20 g) which was used directly for the next step. To a pre-prepared actived ester solution [Boc-Asn-OH (1.16 g, 5.0'mniol), HOBT (0.70 g, 5.0 mmol), EDCI (1.00 g, 5.0 mmol).and DIPEA
(1.75 mL, 10 mmol) was mixture in dry DCM (25 mL) and stirred at r.t. for 15 mins], free amino (0.75 g, 5.0 nunol) was added, the mixture was stirred at r.t. overnight. Ethyl acetate (200 mL) was added, washed by water and brine, dried over anhydrous Na2SO4, purified by column (silical gel, hexane and ethyl acetate) to afford 22 as a colorless solid 200 mg in 11 % yield over 2 steps. . iH NMR (CDC13) 8 6.94 (1 H, s), 6.29 (1 H, s), 6.20 (1 H, d, J= 6.4 Hz), 5.84 (1 H, m), 5.64 (1 H, s), 5.10 (2 H, m), 4.45 (1 H, m), 3.17 (2 H, in), 2.94.(1 H, dd, J=
15.2, 3.6 Hz), 2.55 (1 H, dd, J= 15.4, 6.2 Hz), 2.03 (2 H, m), 150 -1.20 (19 H, m); FAB-MS (+VE) m/z 368.4 (MH).
[0099] Preparation of 23. To a solution of 22 (47 mg, 0.128 mmol) in DCM (1.50 mL), was added TES (0.32 mL) and TFA (0.80 mL), the mixture was stirred at r.t. for 1.5 hrs. the solvent was removed in vacuo and the residue was used directly. To a solution of pre-prepared actived ester of 25 [a mixtue of 25 (72 mg, 0.116 mmol), HOAT (19 mg, 0.140 mmol), EDCI (28 mg, 0.140 mmol) and DIPEA (91 L, 0.522 mmol) in DMF (4.0 mL) was stirred at r.t. for 15 mins], was added a solution of free amine in DMF (2.0 mL), the mixture was stirred at r.t. for 18 hrs. Ethyl acetate (100 mL) was added to the reaction mixture, washed by water and brine, dried over anhydrous Na2SO4, purified by column'(silica gel, chloroform and methanol) to afford 23 as a colorless solid 60 mg in 60% yield.
(CDC13) 8 7.27 - 7.16 (5 H, m), 7. 10 (1 H, m), 6.67 (1 H, s), 6.00 (1 H, s), 6.00 -5.80(2H, m),5:40(1H,s),5.12-5.05(4H,rn),4.55(1H,m),3.50(1H,t,J14.0Hz),3.25(1H, dd,J=13.2,6.8Hz),3.10-2.95(4H,m),2.83-2.70(2H,m),2.64(2H,m),2.08(2H, m), 1.90 = 1.10 (47 H, m); FAB-MS (+VE) m/z 871.6 (MH}).
[00100] Preparation of 24. The solution of 23 (60 mg, 0.069 mmol) in dichloroethane (35 mL) was degassed for 5 mins under Ar, Grubbs's catalyst II (30 mg) was added, and the mixture was refluxed for 24 hrs. The solvent was removed in vacuo, the residue was purified by column (silical gel, hexane and ethyl acetate); the crude product was treated with TFA (9.5 mL); H20 (0.5 mL) and TES (0.50 mL) at r.t. for 2 hrs, the final product was purified by HPLC, after lyophilized, 24 was got as a white 'power, 8 mg, 17%
yield over 2 steps.1H NMR (CDC13) 8 8.36 (2 14, m), 7.55 (1 H, s) 7.30 (2 H, AB, JAB = 8.0 Hz), 7.19 (2 H, AB, JAB = 8.0 Hz), 7.16 (1 H, s), 6.59 (1 H, m), 5.80 (1 H, dd, J= 15.2, 9.6 Hz), 5.66 (1 H, m), 4.28 (1 H, m), 4.13 (1 H, m), .3.60 (2 H, m) 3.16 (1 H, m), 2.90 (2 H, d; J= 21.2 Hz), 2.77 (2 H, m), 2.36 (1 H, dd, J= 16.0, 4.8 Hz), 2.20 (1 H, m), 2.07 - 1.94 (2 H, m), 1.90 -1.40 (20 H, m); FAB-MS (-VE) rn/z 673.4 (M-H)-.
[00101] This example illustrates a property of compounds in accordance with an embodiment of the invention.
[00102] Biosensor Analysis: Binding experiments were performed on a Biacore instrument (Biacore Inc., Piscataway NJ). All Biotinylated Grb2 SH2 domain proteins (b-Grb2) were expressed and purified (Protein Expression Laboratory and The Protein Chemistry Laboratory, SAIC - Frederick). The b-Grb2 was immobilized onto carboxymethyl 5' dextran surface (CM5 sensor chip, Biacore Inc.) by amine coupling. The lyophilized b-Grb2 was reconstituted in fifty percent DMSO in H20 to make a stock solution of 1mg/rnL and stored at -80 C. A 1: 12.5 dilution of b-Grb2 was used for immobilization, by dilution in acetate buffer pH-5.0, with 5% DMSO. IXPBS
(phosphate buffered saline, pH 7.4) was used as the running buffer.
[00103] An immobilization wizard was used to optimize the immobilization target. For b-Grb2, 2500-5000 resonance units (RU) of protein were captured on the CM5 sensor chip.
Small molecules were serially diluted in running buffer to the concentrations (1.25 nM -1500 nM). as indicated in each sensorgram and injected at 25 C at a flow rate. of 30 L/min for 2 minutes. Varying concentrations of small molecules were injected in increasing concentrlqtions, and every injection was performed in duplicate within each experiment. In order to subtract background noise from each data set, all samples were also 'run over an unmodified reference surface and random injections of running buffer were performed throughout every experiment ("double referencing"). Data were fit to a simple 1: 1 interaction model, using the global data analysis program CLAMP; Myszka et al., Trends Bioclaena. Sci. 1995, 23, 149-150.
[00104] , Effect of Macrocyclization on Grb2 SH2 Domain Bindin'g Affinity.
Using plasmon resonance techniques, steady state KD values were obtained for direct binding of peptides 2, 3 and 4 to chip-bound Grb2 SH2 domain protein. Relative to the open-chain compound 2 (5610 ~: 75.0 nM), macrocycles 3 (KD = 22.7 0.455 nM) and 4 (54.9 0.945 nM) provided two orders of magnitude potency enhancements.
[00105] Grb2 SH2 Domain-Binding Affinity. Binding affinity of 24 to Grb2 SH2 domain protein was determined. Complex binding kinetics were observed with Kd values of 9.3 10.1 nM and 21.3 0.5 M, respectively.
[00106] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
[00107] - The use of the terms "a" and "an" and "the" and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms "comprising," "having,"
"including," and "containing" are to be construed as open-ended terms (i.e., meaning "including, but not limited to,") unless otherwise noted.' Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein.
All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed..' No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
[00108] Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropri4te, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any corimbination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or othervvise- clearly contradicted by context.
Claims (42)
1. A compound of formula (I):
wherein R1 is a lipophile; R2, in combination with the phenyl ring, is a phenylphosphate mimic group or a protected phenylphosphate mimic group; R3 is hydrogen, azido, amino, oxalylamino, carboxy C1-C6 alkyl, C1-C6 alkoxycarbonyl C1-C6 alkyl, aminocarbonyl C1-C6 alkyl, or C1-C6 alkyl carbonylamino; wherein the alkyl portion of R3 may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof; R6 is a linker; AA is an amino acid or fragment thereof; and n is 1 to 6; or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof.
wherein R1 is a lipophile; R2, in combination with the phenyl ring, is a phenylphosphate mimic group or a protected phenylphosphate mimic group; R3 is hydrogen, azido, amino, oxalylamino, carboxy C1-C6 alkyl, C1-C6 alkoxycarbonyl C1-C6 alkyl, aminocarbonyl C1-C6 alkyl, or C1-C6 alkyl carbonylamino; wherein the alkyl portion of R3 may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof; R6 is a linker; AA is an amino acid or fragment thereof; and n is 1 to 6; or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof.
2. The compound of claim 1, wherein n is 2 or 3.
3. The compound of claim 1 or 2 having the formula (Ia):
wherein R1 is a lipophile; R2, in combination with the phenyl ring, is a phenylphosphate mimic group or a protected phenylphosphate mimic group; R3 is hydrogen, azido, amino, oxalylamino, carboxy C1-C6 alkyl, C1-C6 alkoxycarbonyl C1-C6 alkyl, aminocarbonyl C1-C6 alkyl, or C1-C6 alkyl carbonylamino; wherein the alkyl portion of R3 may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof; R4 and R5, independently, are hydrogen, C1-C6 alkyl, C4-C8 cycloalkyl, or heterocyclyl, or R4 and R5 together-form a C4-C8 cycloalkyl or heterocyclyl.
R6 is a linker; AA is an amino acid or fragment thereof; and n is 1 to 6; or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof.
wherein R1 is a lipophile; R2, in combination with the phenyl ring, is a phenylphosphate mimic group or a protected phenylphosphate mimic group; R3 is hydrogen, azido, amino, oxalylamino, carboxy C1-C6 alkyl, C1-C6 alkoxycarbonyl C1-C6 alkyl, aminocarbonyl C1-C6 alkyl, or C1-C6 alkyl carbonylamino; wherein the alkyl portion of R3 may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof; R4 and R5, independently, are hydrogen, C1-C6 alkyl, C4-C8 cycloalkyl, or heterocyclyl, or R4 and R5 together-form a C4-C8 cycloalkyl or heterocyclyl.
R6 is a linker; AA is an amino acid or fragment thereof; and n is 1 to 6; or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof.
4. The compound of any one of claims 1-3, wherein R1 is selected from the group consisting of alkyl, alkoxy, alkenyl, alkynyl, aryl, aryloxy, aryl alkoxy, alkylaryl, alkyloxy aryl, arylalkyl, alkylamino, arylalkylamino, alkenylamino, arylamino, aryloxy alkyl, heterocyclyl, heterocyclyloxy, aryl heterocyclyl alkyl, heterocyclyl alkyl, heterocyclyl alkoxy, aryl heterocyclyl, aryl heterocyclyloxy, alkyl arylalkyl, alkoxy arylalkyl, and alkoxy arylalkoxy, and any combination thereof, optionally substituted or in combination with one or more groups such as alkyl, keto, ester, amino, aminocarbonyl, ureido, hydroxyl, thiol, cyano, alkoxy, and halo.
5. The compound of any one of claims 1-4, wherein R1 is C1-C6 alkyl carbonyl, C6-C14 aryl carbonyl, C6-C14 aryl C1-C6 alkyl carbonyl, C6-C14 aryl C1-C6 alkylamino carbonyl, C6-C14 aryl C1-C6 alkyl, C6-C14 aryl heterocyclyl C1-C6 alkyl, C6-C14 aryl heterocyclyl C1-C6 alkyl carbonyl, C1-C6 alkylaminocarbonyl, C2-C6 alkenylaminocarbonyl, C6-C14 arylaminocarbonyl, C1-C6 alkoxy C1-C6 alkyl, C1-C6 alkoxy C1-C6 alkyl carbonyl, C6-C14 aryloxy C1-C6 alkyl, C6-C14 aryloxy C1-C6 alkyl carbonyl, C6-C14 aryl C1-C6 alkoxy C1-C6 alkyl, or C6-C14 aryl C1-C6 alkoxy C1-C6 alkyl carbonyl, wherein the aryl portion is unsubstituted or substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof.
6. The compound of any one of claims 1-5, wherein R1 is C1-C6 alkyl carbonyl, C6-C14 aryl carbonyl, C6-C14 aryl C1-C6 alkyl carbonyl, C6-C14 aryl C1-C6 alkylamino carbonyl, C6-C14 aryl heterocyclyl C1-C6 alkyl carbonyl, C1-C6 alkylaminocarbonyl, C2-C6 alkenyl aminocarbonyl, C6-C14 arylamino carbonyl, C1-C6 alkoxy C1-C6 alkyl carbonyl, aryloxy C1-C6 alkyl carbonyl, or C6-C14 aryl C1-C6 alkoxy C1-C6 alkyl carbonyl, wherein the aryl portion is unsubstituted or substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof;
7. The compound of any one of claims 1-6, wherein R2 is hydroxyl, carboxyl, formyl, carboxy C1-C6 alkyl, carboxy C1-C6 alkoxy, dicarboxy C1-C6 alkyl, dicarboxy C1-alkyloxy, dicarboxyhalo C1-C6 alkyl, dicarboxyhalo C1-C6 alkyloxy, phosphono, phosphono C1-C6 alkyl, phosphonohalo C1-C6 alkyl, phosphoryl, phosphoryl C1-C6 alkyl, and phosphoryl C1-C6 alkoxy, carboxy C1-C6 alkylamino, oxalylamino, RSO2NH-wherein R
can be C1-C6 alkyl, halo C1-C6 alkyl, C6-C14 aryl, C6-C14 aryl C1-C6 alkyl, or trifluoro C1-C6 alkyl; C6-C14 aryl C1-C6 alkyl, phosphino C1-C6 alkyl, C1-C6 alkyl phosphino C1-C6 alkyl, C6-C14 aryl, and C6-C14 aryl C1-C6 alkyl, wherein the alkyl and alkoxy portions of R2 may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof.
can be C1-C6 alkyl, halo C1-C6 alkyl, C6-C14 aryl, C6-C14 aryl C1-C6 alkyl, or trifluoro C1-C6 alkyl; C6-C14 aryl C1-C6 alkyl, phosphino C1-C6 alkyl, C1-C6 alkyl phosphino C1-C6 alkyl, C6-C14 aryl, and C6-C14 aryl C1-C6 alkyl, wherein the alkyl and alkoxy portions of R2 may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof.
8. The compound of any one of claims 1-7, wherein R2 is hydroxyl, carboxyl, formyl, carboxy C1-C6 alkyl, carboxy C1-C6 alkoxy, dicarboxy C1-C6 alkyl, dicarboxy C1-alkyloxy, dicarboxyhalo C1-C6 alkyl, dicarboxyhalo C1-C6 alkyloxy, phosphono, phosphono C1-C6 alkyl, phosphonohalo C1-C6 alkyl, phosphoryl, phosphoryl C1-C6 alkyl, or phosphoryl C1-C6 alkoxy, wherein the alkyl and alkoxy portions may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof.
9. The compound of any one of claims 3-8, wherein R4 and R5 together form a C4-cycloalkyl.
10. The compound of any one of claims 3-9, wherein R4 and R5 together form cyclohexyl.
11. The compound of any one of claims 1-10, wherein R6 is a group having 1-6 carbon atoms, which may be optionally have a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof.
12. The compound of any one of claims 1-11, wherein R6 is a C2-C6 alkenylenyl or C2-C6 alkynylenyl group, which may optionally have a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof.
13. The compound of any one of claims 1-12, wherein R6 is a C2-C6 alkenylenyl.
14. The compound of any one of claims 3-13 having the formula:
15. The compound of any one of claims 3-14, wherein R1 is C1-C6 alkyl carbonyl, C6-C14 aryl carbonyl, C6-C14 aryl C1-C6 alkyl carbonyl, C6-C14 aryl C1-C6 alkylamino carbonyl, C6-C14 aryl heterocyclyl C1-C6 alkyl carbonyl, C1-C6 alkylaminocarbonyl, CZ-C6 alkenylaminocarbonyl, C6-C14 arylamino carbonyl, C1-C6 alkoxy C1-C6 alkyl carbonyl, C6-C14 aryloxy C1-C6 alkyl carbonyl, or C6-C14 aryl C1-C6 alkoxy C1-C6 alkyl carbonyl, wherein the aryl portion is unsubstituted or substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof;
R2 is hydroxyl, carboxyl, formyl, carboxy C1-C6 alkyl, carboxy C1-C6 alkoxy, dicarboxy C1-C6 alkyl,'dicarboxy C1-C6 alkyloxy, dicarboxyhalo C1-C6 alkyl, dicarboxyhalo alkyloxy, phosphono, phosphono C1-C6 alkyl, phosphonohalo C1-C6 alkyl, phosphoryl, phosphoryl C1-C6 alkyl, or phosphoryl C1-C6 alkoxy, wherein the alkyl and alkoxy portions may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof, R3 is hydrogen, azido, amino, oxalylamino, carboxy C1-C6 alkyl, C1-C6 alkoxycarbonyl C1-C6 alkyl, aminocarbonyl C1-C6 alkyl, or C1-C6 alkylcarbonylamino; wherein the alkyl portion of R3 may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof;
R4 and R5, independently, are hydrogen, C1-C6 alkyl, cycloalkyl, heterocyclyl, or together form cycloalkyl or heterocyclyl, wherein the cycloalkyl is a C3-C7 cycloalkyl, and the heterocyclyl is a 3-7 membered ring with at least one of N, O, and S; and R6 is a C2-C6 alkenylenyl or C2-C6 alkynylenyl group, which may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof.
R2 is hydroxyl, carboxyl, formyl, carboxy C1-C6 alkyl, carboxy C1-C6 alkoxy, dicarboxy C1-C6 alkyl,'dicarboxy C1-C6 alkyloxy, dicarboxyhalo C1-C6 alkyl, dicarboxyhalo alkyloxy, phosphono, phosphono C1-C6 alkyl, phosphonohalo C1-C6 alkyl, phosphoryl, phosphoryl C1-C6 alkyl, or phosphoryl C1-C6 alkoxy, wherein the alkyl and alkoxy portions may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof, R3 is hydrogen, azido, amino, oxalylamino, carboxy C1-C6 alkyl, C1-C6 alkoxycarbonyl C1-C6 alkyl, aminocarbonyl C1-C6 alkyl, or C1-C6 alkylcarbonylamino; wherein the alkyl portion of R3 may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof;
R4 and R5, independently, are hydrogen, C1-C6 alkyl, cycloalkyl, heterocyclyl, or together form cycloalkyl or heterocyclyl, wherein the cycloalkyl is a C3-C7 cycloalkyl, and the heterocyclyl is a 3-7 membered ring with at least one of N, O, and S; and R6 is a C2-C6 alkenylenyl or C2-C6 alkynylenyl group, which may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof.
16. The compound of claim 14 or 15, wherein R6 is C2-C6 alkenylenyl, which may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof.
17. The compound of claim 16, wherein R6 is C2-C4 alkenylenyl.
18. The compound of any one of claims 1-17, wherein R1 is C6-C14 aryl C1-C6 alkylamino carbonyl.
19. The compound of any one of claims 1-18, wherein R1 is C1o aryl C1-C6 alkylaminocarbonyl.
20. The compound of any one of claims 1-19, wherein R1 is naphthylmethylaminocarbonyl.
21. The compound of any one of claims 1-20, wherein R2 is phosphono C1-C6 alkyl, optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, alkyl, alkoxy, and keto, and any combination thereof.
22. The compound of any one of claims 1-21, wherein R2 is phosphonomethyl.
23. The compound of any one of claims 1-22, wherein R3 is carboxy C1-C6 alkyl.
24. The compound of any one of claims 1-23, wherein R3 is carboxymethyl.
25. The compound of any one of claims 1-24, wherein R6 is allyl.
26. The compound of claim 1 or 2, wherein said amino acids (AA)n are selected from the group consisting of glycine, alanine, valine, norvaline, leucine, iso-leucine, norleucine, .alpha.-amino n-decanoic acid, serine, homoserine, threonine, methionine, cysteine, S-acetylaminomethyl-cysteine, proline, trans-3- and trans-4-hydroxyproline, phenylalanine, tyrosine, 4-aminophenylalanine, 4- nitrophenylalanine, 4-chlorophenylalanine, carboxyphenylalanine, .beta.-phenylserine, .beta.-hydroxyphenylalanine, phenylglycine, .alpha.-naphthylalanine, cyclohexylalanine, cyclohexylglycine, tryptophan, indoline-2-carboxylic acid, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, aspartic acid, asparagine, aminomalonic acid, aminomalonic acid monoamide, glutamic acid, glutamine, histidine, arginine, lysine, N'-benzyl-N'-methyl-lysine, N',N'-dibenzyl-lysine, 6-hydroxylysine, ornithine, .alpha.-aminocyclopentane carboxylic acid, .alpha.-aminocyclohexane carboxylic acid, .alpha.-aminocycloheptane carboxylic acid, .alpha.-(2-amino-2-norbornane)-carboxylic acid, .alpha.,.gamma.-diaminobutyric acid and .alpha.,.beta.-diaminopropionic acid, homophenylalanine, and .alpha.-tert-butylglycine, and any combination thereof.
27. The compound of claim 26, wherein said amino acids are asparagine and .alpha.-aminocyclohexane carboxylic acid.
28. A compound of the formula II:
wherein R1 and R1' are the same and are C1-C6 alkyl or R1 and R1' together form a C4-C8 cycloalkyl; R2, in combination with the phenyl ring, is a phenylphosphate mimic group or a protected phenylphosphate mimic group; R3 is hydrogen, azido, amino, oxalylamino, carboxy C1-C6 alkyl, C1-C6 alkoxycarbonyl C1-C6 alkyl, aminocarbonyl C1-C6 alkyl, or C1-C6 alkyl carbonylamino; wherein the alkyl portion of R3 may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof;
R4 and R5, independently, are hydrogen, C1-C6 alkyl, C4-C8 cycloalkyl, or heterocyclyl, or R4 and R5 together form a C4-C8 cycloalkyl or heterocyclyl;
R6 is a group having 1-6 carbon atoms, which may be optionally have a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof; and m is 1 or 2;
or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof.
wherein R1 and R1' are the same and are C1-C6 alkyl or R1 and R1' together form a C4-C8 cycloalkyl; R2, in combination with the phenyl ring, is a phenylphosphate mimic group or a protected phenylphosphate mimic group; R3 is hydrogen, azido, amino, oxalylamino, carboxy C1-C6 alkyl, C1-C6 alkoxycarbonyl C1-C6 alkyl, aminocarbonyl C1-C6 alkyl, or C1-C6 alkyl carbonylamino; wherein the alkyl portion of R3 may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof;
R4 and R5, independently, are hydrogen, C1-C6 alkyl, C4-C8 cycloalkyl, or heterocyclyl, or R4 and R5 together form a C4-C8 cycloalkyl or heterocyclyl;
R6 is a group having 1-6 carbon atoms, which may be optionally have a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof; and m is 1 or 2;
or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof.
29. The compound of claim 28, wherein m is 1.
30. The compound of claim 28 or 29, wherein R1 and R1' together form a C4-C8 cycloalkyl.
31. The compound of claim 30, wherein R1 and R1' together form cyclohexyl.
32. The compound of any of claims 28-31, wherein R2 is hydroxyl, carboxyl, formyl, carboxy C1-C6 alkyl, carboxy C1-C6 alkoxy, dicarboxy C1-C6 alkyl, dicarboxy C1-alkyloxy; dicarboxyhalo C1-C6 alkyl, dicarboxyhalo C1-C6 alkyloxy, phosphono, phosphono C1-C6 alkyl, phosphonohalo C1-C6 alkyl, phosphoryl, phosphoryl C1-C6 alkyl, and phosphoryl C1-C6 alkoxy, carboxy C1-C6 alkylamino, oxalylamino, RSO2NH-wherein R
can be C1-C6 alkyl, halo C1-C6 alkyl, C6-C14 aryl, C6-C14 aryl C1-C6 alkyl, or trifluoro C1-C6 alkyl, C6-C14 aryl C1-C6 alkyl, phosphino C1-C6 alkyl, C1-C6 alkyl phosphino C1-C6 alkyl, C6-C14 aryl, and C6-C14 aryl C1-C6 alkyl, wherein the alkyl and alkoxy portions of R2 may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof.
can be C1-C6 alkyl, halo C1-C6 alkyl, C6-C14 aryl, C6-C14 aryl C1-C6 alkyl, or trifluoro C1-C6 alkyl, C6-C14 aryl C1-C6 alkyl, phosphino C1-C6 alkyl, C1-C6 alkyl phosphino C1-C6 alkyl, C6-C14 aryl, and C6-C14 aryl C1-C6 alkyl, wherein the alkyl and alkoxy portions of R2 may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof.
33. The compound of any one of claims 28-32, wherein R4 and R5 together form a cycloalkyl.
34. The compound of any one of claims 28-33, wherein R4 and R5 together form cyclohexyl.
35 35. The compound of any of claims 28-34, wherein R6 is a C2-C6 alkenylenyl or alkynylenyl group, which may optionally have a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C1-C6 alkyl, C1-C6 alkoxy, and keto, and any combination thereof.
36. The compound of any of claims 28-35, wherein R3 is carboxy C1-C6 alkyl.
37. The compound of claim 36, wherein R3 is carboxy methyl.
38. The compound of claim 28, which has the formula IIa:
39. A pharmaceutical composition comprising a compound of any one of claims 1-38 and a pharmaceutically acceptable carrier.
40. A method for inhibiting an SH2 domain-containing protein from binding with a phosphoprotein comprising contacting the SH2 domain-containing protein with a compound of any one of claims 1-38.
41. The method of claim 40, wherein the SH2 domain-containing protein is a Grb2 protein, Shp2 protein, or a STAT3 protein.
42. A method for treating a disease mediated by the binding of an SH2 domain-containing protein with a phosphoprotein, wherein the method. comprises administering to a mammal afflicted with said disease an effective amount of a compound of any one of claims 1-38.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61480004P | 2004-09-30 | 2004-09-30 | |
US60/614,800 | 2004-09-30 | ||
PCT/US2005/035246 WO2006039527A1 (en) | 2004-09-30 | 2005-09-30 | Macrocyclic sh2 domain binding inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2582908A1 true CA2582908A1 (en) | 2006-04-13 |
Family
ID=35999421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002582908A Abandoned CA2582908A1 (en) | 2004-09-30 | 2005-09-30 | Macrocyclic sh2 domain binding inhibitors |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1793843A1 (en) |
AU (1) | AU2005291957A1 (en) |
CA (1) | CA2582908A1 (en) |
WO (1) | WO2006039527A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008067270A1 (en) * | 2006-11-27 | 2008-06-05 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Macrocyclic grb2 sh2 domain-binding inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1383792A2 (en) * | 2000-08-22 | 2004-01-28 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Sh2 domain binding inhibitors |
WO2004003005A2 (en) * | 2002-06-28 | 2004-01-08 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Sh2 domain binding inhibitors |
US20050119163A1 (en) * | 2003-09-18 | 2005-06-02 | The Government Of The United States Of America, As Represented By The Secretary, | SH2 domain binding inhibitors |
-
2005
- 2005-09-30 WO PCT/US2005/035246 patent/WO2006039527A1/en active Application Filing
- 2005-09-30 AU AU2005291957A patent/AU2005291957A1/en not_active Abandoned
- 2005-09-30 CA CA002582908A patent/CA2582908A1/en not_active Abandoned
- 2005-09-30 EP EP05805719A patent/EP1793843A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1793843A1 (en) | 2007-06-13 |
WO2006039527A1 (en) | 2006-04-13 |
AU2005291957A1 (en) | 2006-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004005248A1 (en) | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) | |
KR20070091611A (en) | Tripeptide and tetrapeptide sulfones | |
EP4309741A1 (en) | Cyclic compound having inhibitory effect selective for kras but not for hras and nras | |
WO2018165575A2 (en) | Warhead-containing peptidomimetic macrocycles as modulators of bfl-1 | |
US20080139456A1 (en) | Macrocyclic Sh2 Domain Binding Inhibitors | |
US7825216B2 (en) | Phenylanine derivatives | |
WO2017218922A2 (en) | Compositions and methods for the treatment of bacterial infections | |
EP3749365A2 (en) | Peptidyl inhibitors of calcineurin-nfat interaction | |
HUT77979A (en) | Peptides, process for producing them and pharmaceutical compositions containing them | |
WO2023214576A1 (en) | Cyclic compound having selective kras inhibitory effect on hras and nras | |
CA2582908A1 (en) | Macrocyclic sh2 domain binding inhibitors | |
FI89062B (en) | FRAMEWORK FOR THE ADMINISTRATION OF THERAPEUTIC ANALYZED SOMATOSTATIN ANALOGGER | |
US6977241B2 (en) | SH2 domain binding inhibitors | |
US20110311564A1 (en) | Method for Producing Intermediates for the Production of Novel Macrocycles that are Inhibitors of the Proteasomic Degradation of p27, such as Argyrin and Derivatives Thereof, and Uses of Said Macrocycles | |
WO2008067270A1 (en) | Macrocyclic grb2 sh2 domain-binding inhibitors | |
US7767645B2 (en) | SH2 domain binding inhibitors | |
TWI820038B (en) | Process for the preparation of tubulysins and intermediates thereof | |
US7425537B2 (en) | SH2 domain binding inhibitors | |
Kijewska et al. | Stapling of leu-enkephalin analog with bifunctional reagent for prolonged analgesic activity | |
WO2024101402A1 (en) | Pharmaceutical composition containing cyclic compound having selective kras inhibitory effect against hras and nras | |
WO2022170108A1 (en) | Peptidomimetic macrocycles and uses thereof in prevention of radiation injury | |
US7226991B1 (en) | Phenylalanine derivatives | |
WO2004003005A2 (en) | Sh2 domain binding inhibitors | |
RU2144038C1 (en) | Peptide used for inhibition of pepsin release, pharmaceutical composition | |
JP2024069167A (en) | Pharmaceutical composition containing a cyclic compound having selective KRAS inhibitory activity against HRAS and NRAS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |